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           The neonatal Fc receptor for IgG (FcRn), a major histocompatibility complex 
(MHC) class I-related molecule, plays an important role in IgG transport and 
protection. The transport of IgG across epithelial and endothelial barriers and the IgG 
homeostasis maintained by FcRn contributes to the effective humoral immunity. Thus, 
the level of FcRn itself will affect the IgG-associated immune responses. 
           Although FcRn is expressed in a variety of tissues and cell types, the extent to 
which FcRn expression is regulated by immunological and inflammatory events 
remains unknown.I showed here that FcRn was up-regulated by the stimulation of 
inflammatory cytokines or Toll-like receptor ligands in human peripheral blood 
mononuclear cell (PBMC) and THP-1 cell line. By chromatin immunoprecipitation, I 
identified three NF-κB binding sites within introns 2 and 4 of the human FcRn gene. These 
intronic binding sites boost FcRn transcription activities through looping with the promoter 
region. In contrast, FcRn expression was down-regulated by Th1 cytokine IFN-γ, and the 
down-regulation of FcRn was not caused by apoptosis or the instability of FcRn mRNA. It 
  
has been demonstrated that IFN-γ activated STAT1 bound with GAS sequence in human 
FcRn promoter, and which blocked the transcriptional machinery.  
           Fc gamma receptors (FcγRs) expressed in macrophages (MФ) and dendritic cells 
(DCs) can mediate antigen presentation in both MHC class II and MHC class I 
pathways. We tested here the role for FcRn in antigen presentation of IgG-restricted 
Immune complexes (ICs). It was observed that the expression of FcRn in MФ, but not 
in DC enhanced the phagosomal ICs antigen presentation to CD4 T cells. A low pH 
value in phgosome of MФ facilitated FcRn binding to ICs, stabilizing the antigens and 
promoting the efficient MHC II –peptide assembly. However, the alkalized 



























THE FUNCTIONAL REGULATION OF FCRN EXPRESSION AND FCRN-













Dissertation submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 













Associate Professor Xiaoping Zhu, Chair 
Professor David M. Mosser 
Assistant Professor Kenneth Frauwirth 
Professor Siba K, Samal 








































This dissertation is dedicated to my parents, my sister, my wife, my baby girl Sheila.  
I couldn’t have done this without you. Thank you so much for everything you’ve given 




                                               Acknowledgements 
           First, I would like to thank my advisor, Xiaoping Zhu. His support and guidance 
throughout the years has given me the knowledge and abilities to explore the unknown. 
His true passion for science has impressed me. What he has done sets up the great 
example leading me through my future endeavors. Also, I would like to thank the 
members of my dissertation committee: Kenneth Frauwirth, Wenxia Song, David 
Mosser, and Sibal Samal. I appreciate all of your suggestions, constructive criticism, 
and encouraging remarks throughout my graduate study. 
        I would like to thank all of members of the Zhu lab for their help, kindness and 
support. I am grateful to Lilin Ye, his valuable protein handling skills and advices helps 
me so much over the years. The IgG-transcytosis experiments benefit me and the lab a 
lot; even though I am the only one in the lab don’t know how to handle this experiment. 
Dr.Li Lu, Dr.Zili Li and Yu Bai, Thank you for everything. I appreciated it more than 
you know.  I am grateful to Rongyu Zengand Senthilkumar for all your help. I will not 
finish my thesis without your support on mouse housing and bedding changes. 
          My sincere appreciation goes to Ireen Dryburgh-Barry, Daniel Rockmann and 
Kadavil Kumar for their support and friendship. 
        I extend my thanks to my colleagues in Dr. Mosser’s lab, Xia Zhang, Jinshan Cao 
and Ziyan Yang. Your support and friendship keep me sane in all these years. I am 
lucky to have friends like you. You are the best! 
          Finally, I’d like to thank my family. I don’t know where I’d be without the love 
and support you have given me all these years.  I am especially grateful to my wife, 












TABLE OF CONTENTS………………………………………………………......iv 
 
LIST OF TABLES………………………………………………………..………...ix 
 
LIST OF FIGURES…………………………………………………………………x 
 
   LIST OF ABBREVIATIONS……………………………………………………...xii 
 
   CHAPTER 1: INTRODUCTION…………………………………………………..1 
  
     OVERVIEW...........................................................................................................1 
 
     Immunoglobulins....................................................................................................1 
 
                 IgG and FcγRs........................................................................................................2 
 The Neonatal Fc Receptor (FcRn)........................................................................4 
FcRn belongs to MHC class I family...............................................................4 
The interaction of IgG with FcRn....................................................................7 
The interaction of FcγRs with IgG is different from FcRn............................9 
The FcRn-mediated transportation of IgG......................................................10 
FcRn-mediated IgG/albumin protection from catablism...............................12 
FcRn, as therapeutic target for autoimmune diseases....................................13 
Transcriptional regualtion......................................................................................15 
The nuclear factor-κB (NF-kB) and inhibitors of NF-kB (IkBs) .................15 





JAKs ( Janus family tyrosine kinases)-STATs  
(Signal transducer and activitor of transcription).........................................19 
 
Antigen presentation.................................................................................................21 
MHC class I-restricted antigen presentation..................................................21  
MHC class II-restricted antigen presentation................................................22 
Macrophage and DC.........................................................................................23 
QUESTIONS TO BE ADDRESSED IN MY PROJECT....................................24 
CHAPTER 2: NF-κB SIGNALING REGULATES FUNCTIONAL 
EXPRESSION OF FcRn via INTRONIC BINDING SEQUENCE……………. 26 
 
    ABSTRACT............................................................................................................26 
 
    INTRODUCTION.................................................................................................27 
  
MATERIALS AND METHODS..........................................................................29 
 
                Cell lines, antibodies, reagents.............................................................................29 
                Gel electrophoresis, Western blot, and IgG binding assay...............................31 
                Chromatin immunoprecipitation (ChIP)............................................................32 
                Construction of expression or reporter plasmids and mutagenesis.................32 
                Transient transfection and Luciferase assay......................................................33 
                Chromosome conformation capture (3C) assay ................................................33 
                RESULTS...............................................................................................................34 
                Up-regulation of FcRn expression by TNF-α ....................................................34 
    Regulation of FcRn expression in THP-1 cells by a TLR-mediated  
    signaling pathway..................................................................................................36 
 
                Effect of NF-κB inhibition on FcRn expression..................................................38 
                Screening for NF-κB binding sites adjacent to the FcRn gene..........................40 




                expression of the luciferase .................................................................................42 
                
                Mutual interactions between promoter and intronic NF-κB of human  
                FcRn gene..............................................................................................................44 
                          
DISCUSSION.........................................................................................................48 
 
CHAPTER 3:  TRANSCRIPTIONAL REPRESSION OF FCRN BY IFN-γ  
THROUGH JAK-STAT-1 SIGNALING PATHWAY …………………….….….55 
 
                ABSTRACT..........................................................................................................55 
                INTRODUCTION...............................................................................................56 
                MATERIALS AND METHODS........................................................................57 
                
                Cell lines, antibodies, reagents...........................................................................57 
 
    Semiquantitative RT-PCR and quantitative real-time RT-PCR....................58 
                Construction of expression or reporter plasmids and mutagenesis................59 
    Immunoprecipitation, gel electrophoresis, and Western blotting...................60 
                Determination of mature FcRn mRNA stability...............................................61            
                Nuclear run-on assay...........................................................................................61 
                Immunofluorescence and detection of apoptosis by TUNEL ..........................62 
               Transient transfection and Luciferase assay......................................................64 
   Chromatin immunoprecipitation (ChIP)............................................................64 
    Preparation of nuclear extracts and EMSA......................................................65                                 
                IgG transcytosis ...................................................................................................66 
                Statistical analysis ................................................................................................67 
                RESULTS..............................................................................................................67 
                   
                Exposure of cells with IFN-γ down-regulates  
                the expression of FcRn.........................................................................................67 
                   




                mRNA transcription, and apoptosis ..................................................................68 
      
    Identification of STAT-1 binding site in the FcRn promoter...........................71 
                   
                IFN-γ induces the in vivo association of p300 and STAT-1α, 
                and overexpression of p300 reduces IFN-γ-mediated  
                FcRn gene repression …………………………………......................................75 
                    
                IFN-γ reduced bidirectional transport of IgG in polarized   
                lung epithelial monolayers ..................................................................................80 
                 
                DISCUSSION........................................................................................................82 
 
          CHAPTER 4: FCRN MEDIATES EFFICIENT ANTIGEN PRESENTATION of  
          PHAGOSOMAL IMMUNE COMPLEXES IN MACROPHAGE, BUT NOT IN     
          DENDRITIC CELL………………………………………………………...……….90 
 
                ABSTRACT...........................................................................................................90 
                INTRODUCTION.................................................................................................91 
                MATERIALS AND METHODS..........................................................................93 
                
                Mice........................................................................................................................93 
 
    Reagents.................................................................................................................93 
                Bone marrow-derived dendritic cells (BMDCs) ................................................94 
    Splenic DC (SPDC)................................................................................................94 
                Bone marrow-derived macrophages (BMMs)....................................................95            
                Antigen Presentation Assays................................................................................95 
                Phagosomal pH measurement by confocol microscopy.....................................96 
                Measurement of HRP-immune complex uptake and processing......................97 
    Adoptive transfer with antigen-pulsed DC and macrophages..........................97 
    Analysis of CD4+ T cell proliferation ex vivo.....................................................97                                






                
RESULTS.................................................................................................................98 
                FcRn overlays with immune complexes (ICs) in adult 
                 murine BMDC and BMM.................................................................................98 
                   
                In BMDC, FcRn enhances endocytosed OVA-IC (mono)  
                antigen presentation to MHC class II, but not phagocytosed  
                Latex-OVA-IC.....................................................................................................99 
      
                In BMM, FcRn enhances both endocytosed OVA-IC (mono) and    
                phagocytosed Latex-OVA-IC to MHC class II.................................................101 
                 
                FcRn does not affect the OVA-IC antigen presentation 
                to MHC class I.....................................................................................................104 
                   
                The phagosomal pH is different betweenBMM and BMDC; FcRn can stabilize    
                the internalized ICs in the acidic compartments..............................................106 
                    
                FcRn enhances the ICs antigen presentation ex vivo.......................................108 
                DISCUSSION.......................................................................................................110 
 







LIST OF TABLES 
 
1. Table I.I Characteristics of the IgG Isotype.........................................................3  
2. Table I.II Variations of IgG sequences in the region involved in the binding of 
FcRn.........................................................................................................................8 
3. Table I.III  IgG-mediated autoimmune diseases................................................16 
 
4. Table II.I   3C primers used in this study............................................................49 
 






























LIST OF FIGURES 
 
 
1. Figure 1.1 The structural comparison of FcRn and MHC class I……….….6 
 
2. Figure 1.2 The model for FcRn function………………………………..……14 
 
3. Figure 2.1  FcRn expression in response to cytokine stimulation……………...37 
 
4. Figure 2.2 FcRn expression in response to CpG or LPS stimulation………….39 
 
5. Figure 2.3 Effect of NF-κB inhibitors on the expression of FcRn……………..41 
 
6. Figure 2.4 Mapping of NF-κB binding sequence (s) in human FcRn gene by 
chromatin immunoprecipitation (ChIP) …………..…………………………..43 
 
7. Figure 2.5 NF-κB binding sequences from FcRn introns can enhance the 
transcription of luciferase gene……………………………...…………….…...45 
 
8. Figure 2.6 Chromosome conformation capture (3C) analysis of interaction  
      between promoter and downstream human FcRn gene………….…......…46-47 
 
9. Figure 3.1 Down-regulation of human FcRn expression in epithelial cells 
      by IFN-γ ………………………………………....……………………………..69 
 
10. Figure 3.2. Kinetic studies of FcRn mRNA levels and apoptosis in the  
      absence or presence of IFN-γ…………....................................................…71-72 
 
11. Figure 3.3  Identification of IFN-γ responsive element in human FcRn 
promoter……......................................................................................……...76-77 
 
12. Figure 3.4  IFN-γ induces the in vivo association of p300 and STAT-1 , and 
overexpression of p300 blocks IFN-γ-mediated FcRn gene  
            down-regulation………………………………....……………………….….....79 
 
13. Figure 3.5  Effects of IFN-γ stimulation on the IgG transcytosis……...........81 
 
14. Figure 3.6. Schematic illustration of transcription factors binding to the 
promoter region of some MHC class I-related genes after IFN-γ  
            treatment………………………………....…………………………….....…....88 
 
15. Figure 4.1  Expression of FcRn in endosomal compartments of marine bone 





16. Figure  4.2  FcRn deficiency in BMDC impaired OVA-IC (mono) antigen 
presentation to MHC class II, but not Latex-OVA-IC…....………...............102 
 
17. Figure 4.3  In BMM, FcRn enhances both endocytosed OVA-IC (mono) and 
phagocytosed Latex-OVA-IC to MHC class II…....………...........................103 
 
18. Figure 4.4 MHC class I-restricted antigen presentation is not affected by  
      FcRn deficiency…..............................................................................................105 
 
19. Figure 4.5  BMDC bears a phagosomal alkalinization, while phagosomes  
      in the BMM is acidic ………………………………………………...………..107 
 
20. Figure 4.6 The kinetics of degradation of HRP, HRP-IC, and HRP-Beads-IC  
      in both macrophage and DC…....……….........................................................109 
 
21. Figure 4.7  FcRn defective BMDC  impairs the antigen presentation of  
endocytosed ICs to CD4+ T cell ex vivo, whereas FcRn defective BMM  







LIST OF ABBREVIATIONS 
 
 
antibody dependent immune enhancement                              ADE 
antigen presenting cell                                                             APC 
β2-microglobulin                                                                          β2m 
bone marrow derived dendritic cell                                         BMDC 
bone marrow derived macrophage                                           BMM 
CD4+ T helper cell                                                                    Th 
carboxyfluorescein succinimidyl ester                                     CFSE 
chromatin immunoprecipitation                                                   ChIP 
chromosome conformation capture                                             3C 
cycloheximide                                                                              CHX 
cytotoxic T lymphocyte                                                            CTL 
delayed-type hypersensitivity                                                   DTH 
dendritic cell                                                                              DC 
dulbecco’s modification of eagle’s medium                             DMEM 
electrophoretic mobility-shift assay                                              EMSA 
enzyme Linked Immunosorbent Assay                                     ELISA 
Fc gamma receptor                                                                     FcγR 
fluorescein isothiocyanate                                                          FITC 
heat inactivated fetal calf serum                                                 HI-FCS 
horseradish peroxidase                                                                   HRP 




IFN-stimulated response elements                                             ISRE 
immune complex                                                                        IC 
immunoglobulin G                                                                      IgG 
immunoreceptor tyrosine-based activation motif                       ITAM 
immunoreceptor tyrosine-based inhibitory activation motif      ITIM 
inhibitor of NF-κB                                                                          IκB 
interleukin                                                                                   IL 
interferon gamma                                                                        IFN-γ 
intestinal epithelial cell                                                                    IEC 
Janus tyrosine kinase                                                                     Jak 
lipopolysaccharide                                                                       LPS 
macrophage                                                                                  MФ 
macrophage colony stimulating factor                                        m-CSF 
major histocompatibility complex                                               MHC 
neonatal Fc receptor                                                                         FcRn 
Nuclear factor-kappa B                                                                    NF-κB 
ortho-Nitrophenyl-β-galactoside                                                 ONPG 
ovalbumin                                                                                    OVA 
pathogen associated molecular pattern                                        PAMP 
peripheral blood mononuclear cell                                              PBMC 
protein inhibitor of activated Stat                                                    PIAS 
reverse transcription-PCR                                                               RT-PCR 






suppressor of cytokine signaling                                                   SOCS 
systemic lupus erythematosus                                                         SLE 
T cell receptor                                                                                 TCR 
T regulatory cell                                                                              Treg 
toll-like receptor                                                                              TLR 
 tumor necrosis factor                                                                      TNF 
Terminal deoxynucleotidyl transferase dUTP nick end labeling    TUNEL 
 
 
CHAPTER 1: INTRODUCTION 
   OVERVIEW 
 Immunoglobulins 
 
        Immunoglobulin is the crux of humoral immune responses. Membrane 
immunoglobulins on B cell surface serve as receptors to antigen for B cell. The secreted 
immunoglobulins are able to bind antigen, receptors, and complement to arm and recruit 
effector systems in defense of invading pathogens. Such a wide array of duties performed by 
immunoglobulin is attributed to the feature of its high binding affinity to antigen and Fc 
receptors (1, 2).There are five isotypes of immunoglobulins in mammals: IgM, IgD, IgG, IgA 
and IgE. IgM and IgD, the major component of B cell receptor (BCR), are co-expressed on 
the surface of naive B cells share a number of commonalities to mediate activation, deletion 
and anergy of B cell (3). Pentameic IgM is the first antibody to be secreted upon challenge by 
antigen. The secreted IgD is very rare in the plasma comparing with other isotypes. IgG is the 
predominant immunoglobulin in blood, lymph, peritoneal fluid and cerebrospinal fluid. It 
makes up 75% of serum immunoglobulin (over 30 mg/kg/d). IgG is the only isotype that can 
pass through the human placenta, thereby providing protection to the fetus in utero. The 
majority of synthesized IgA is in the secreted form, which coats the mucosal surface. The 
synthetic rate of IgA is the highest, roughly double that of IgG (4). IgE is the present in 
serum in the lowest concentration of all immunoglobulins. It plays a vital role in the 






IgG and FcγRs 
         IgG is the most abundant and stable isotype of immunoglobulin in serum. The presence 
of high affinity IgG is the hallmark of the secondary humoral immune responses. There are 
four subclasses in the IgG family (human IgG1, IgG2, IgG3, and IgG4; mouse IgG1, IgG2a, 
IgG2b and IgG3). The selection of IgG subclasses does not occur randomly. In human, IgG1 
and IgG2 tend to be against polysaccharide immunogens, while IgG1, IgG3 and IgG4 are 
biased to anti-protein and anti-viral responses (5, 6). In mouse, IgG3 tends to be against 
carbohydrate, IgG1 and IgG2a is for anti-protein and anti-viral (7, 8). This skewness is 
greatly affected by cytokines. These characteristics signify the function of the IgG molecule 
in humoral and cell-mediated immune response (Table I.I) (1).  
 
 IgG communicates with the effector arms of immune system via the Fc receptors 
(FcγR), thereby bridging the cellular and humoral arms of the immune response. 
Macrophages, polymorphonuclear cells and lymphocytes are implicated as important binders 
of IgG. Interaction of IgG with FcγRs on these immunological cells triggers many functional 
effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, 
antigen presentation and inflammation (9).  Signals through FcγRs cytoplasmic tail or their 
associated chains also modulate antigen presentation, cytokine secretion, and cytokine 
receptors or co-stimulatory expression in lymphocyte. The activating Fc receptors, FcγRI, 
FcγRIIa FcγRIII and FcγRIV, contain an immunoreceptor tyrosine-based activation motif 
(ITAM) in their cytoplasmic region or in their associated subunit (9, 10). The inhibitory 
receptor, FcγRIIb contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) (9, 





Table I.I Characteristics of the IgG Isotype. Compilation of the various 
characteristics and functions of the IgG subclasses. 
 
                                    
                              CHARACTERISTICS OF IgG 
 
 
            Subclasses 
                       
                   IgG1, IgG2, IgG3, IgG4 (human) 
                  IgG1, IgG2a, IgG2b, IgG3 (mouse) 
   
  Concentration in Sera 
 
                   
                  IgG1 > IgG2 > IgG3 > IgG4 (human) 
               
 





  High affinity receptor -can bind monomeric IgG 
          FcγRI: IgG3, IgG1 >IgG4>>IgG2 (human) 
                       IgG2a>IgG2b, IgG3>>IgG1 (mouse) 
 
Low affinity receptors –bind IgG-immune complexes 
                      FcγRII: IgG1, IgG2, IgG3 (human) 
                      FcγRIII:IgG1, IgG3 (human) 
            FcγRIV:IgG2a, IgG2b >> IgG1, IgG3 (mouse) 
           
          
           FcRn Binding 
                  
                 IgG4>IgG1>IgG3>IgG2 (human) 
 
                 IgG2a>IgG1>IgG2c>IgG2b (rat) 
 
                 IgG2a>IgG1>IgG3>IgG2b (mouse) 
              
 
              Th Response 
                  
                            Th1: IgG1, IgG3 (human) 
                                      IgG2a (mouse) 
 
                            Th2: IgG4 (human) 
                                     IgG1 (mouse) 
 
 





with high affinity in dendritic cells (DCs), monocytes and macrophages (MΦ). However 
FcγRs bind to different IgG subclasses with different affinity. In humans, high affinity Fc 
receptor FcγRI preferentially binds IgG1 and IgG3 (12). The high affinity of FcγRI depends 
on a third extracellular Ig-like domain. Low affinity FcγRs, FcγRII and III are only capable 
of binding immune complexes. FcγRI and FcγRIII are homodimers that associated with the 
subunit (FcRγ) chain. The formation of homodimer is required for their cell surface 
expression. FcRγ chain is essential for triggering activation signals through FcγRI and 
FcγRIII. FcγRII, in contrast, is a single-chain receptor (9, 11).  FcγRs are important immune 
regulators, FcRγ knockout (KO) mice fail to induce IgG-mediated phagocytosis by MΦ, and 
they also exhibit severe reduction in the autoantibody-dependent experimental hemolytic 
anemia and thrombocytopenia (13), anti-glomerular basement membrane IgG-induced 
glomerulonephritis (14), and immune complex-induced vasculitis syndrome (15). Therefore, 
FcγRs play important roles in shaping the immune response (16-20) and determining the 
outcome of immunopathology (21-25). 
       
The Neonatal Fc Receptor (FcRn).    
 FcRn belongs to MHC class I family 
        It has long been known that passive immunity can be transferred from mother to 
offspring. The neonatal Fc receptor (FcRn) is the first receptor identified in rodent to carry 
out the specific transport of IgG. IgG is the only immunoglobulin transferred from mother to 
the fetus. The gene encoding FcRn was first isolated from rat by Simister & Mostov in 1989. 




each other noncovalently. The sequencing analysis of the heavy-chain confirmed that all 
three extracellular and transmembrane domains of FcRn share homology with the 
corresponding regions of MHC class I molecules (26). This thereby expand the functions of 
MHC class I molecules beyond their known roles in antigen presentation. The fact that 
cytoplasmic domains of FcRn share much less homology with MHC class I molecules is 
consistent with the different functional activities of the two types of proteins (27). 
 
           The structural similarity between FcRn and MHC class I molecules was confirmed by 
the X-ray crystallographic structure (28). Notably, the antigen-binding groove where peptide 
or glycolipid ligand binds is occluded in FcRn (Fig. 1.1). This occlusion is primarily caused 
by a kink which is introduced by the presence of proline at position 165 of the α2 domain 
helix (29). However, the introduction of a proline at the corresponding position in the MHC 
class I molecule H-2d does not affect peptide MHC class I-mediated antigen presentation to  
(30), suggesting that additional structural features of FcRn cause the closed groove. It is 
interesting to explore whether groove on FcRn might be opened up in the acidic condition, 
based on the finding that groove on CD1b can opened up by low pH (31). 
 
          Both mouse and human FcRn alpha chains have been isolated later on (32, 33).  FcRn 
from mouse and rat is highly related and the human form is more divergent, although the 
rodent and human genes share homology. Human FcRn was first identified in human 
syncytiotrophoblast (33-35). This suggests that it plays a role in the transfer of IgGs from the 
maternal circulation to the fetal capillaries of the placental villi (34, 36, 37). The isolation 







                          
                                    FcRn                                           MHC class I 
 
                      
 
      Figure 1.1 The structural comparison of FcRn and MHC class I 







The interaction of IgG with FcRn 
           Characterization of FcRn-IgG interaction sheds light on the mechanism of IgG 
transport. A combination of approaches has been used to identify the IgG interaction site for 
FcRn. Several conserved amino acids located at the CH2-CH3 domain interface of IgG has 
been identified playing a central role in the interaction with rat or mouse FcRn. Ile253, 
His310 in CH2 domain of IgG are key players in the interaction of IgG with FcRn (38-40), 
although the His435 in CH3 plays a minor but significant role in the mouse FcRn-IgG 
interaction (40). Also, the sequence -H-N-H-Y (AA 433-436) of the CH3 domain is 
important for pH-dependent binding. These residues are highly conserved across species, and 
the lack of conservation of this amino acid across species is consistent with more limited 
involvement (40).  Further analyses of resulting recombinant Fc fragments demonstrated that 
amino acids at position 257 and, to a lesser extent, positions 307 and 309 in proximity to the 
CH2-CH3 domain interface play a role in the FcRn-Fc interaction. The role of residues 257, 
307, and 309 is less marked than that of Ile253, His310, and His435 (40, 41). However, 
sequence variations at 257, 307, and 309 can be used to explain the different affinities of rat 
IgGs for FcRn. Furthermore, fragment B of staphylococcal protein A is known to bind to 
amino acids at this interdomain interface; it competes with IgG for binding to FcRn (42) 
(Table I.II).  
 
         The IgG binding site on rat FcRn was mapped using site-directed mutagenesis, the 
mutants were then analyzed by in vitro binding assays (42, 43). These studies identify α2 
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Met  Ile  Ser Arg Thr Pro
Met  Ile  Ser Arg Thr Pro
Met  Ile  Ser Arg Thr Pro
Met  Ile  Ser Arg Thr Pro
Thr Val  Leu His Gln 
Thr Val  Val  His Gln 
Thr Val  Leu  His Gln 
Thr Val  Leu  His Gln 
His  Asn  His  Tyr 
His  Asn  His  Tyr 
His  Asn  Arg Phe








Thr   Ile Thr Leu Thr Pro
Met  Ile  Ser Leu Thr Pro
Met  Ile  Ser Leu Thr Pro
Met  Ile  Ser Leu Thr Pro
Pro  Ile  Met  His Gln  
Pro  Ile  Gln  His Gln 
Pro  Ile  Gln  His Gln 
Pro  Ile  Gln  His Gln 
His  Asn  His His
His  Asn  His His
Lys  Asn  Tyr Tyr








Thr  Ile Thr  Leu  Thr Pro
Thr  Ile Thr  Leu  Thr Pro
Leu  Ile Ser  Gln  Asn Ala
Met  Ile Thr Leu  Thr Pro
Pro  Ile   Leu His Gln 
Pro  Ile  Val  His Arg 
Pro  Ile  Gln  His Gln 
His  Ile  Gln  His Gln 
His  Asn  His His
His  Asn  His His
His  Asn  His His
















Trp133, Glu135, and Asp137) and one β2m residue (Ile1) are shown playing a direct role in  
the interaction, and these residues are reasonably well conserved across species (26, 33, 44). 
 FcRn binds to IgG is a pH dependent manner. The IgG binding occurs at pH<6.5, and the 
dissociation happens at pH>7.5. The highly conserved histidines (His 310 and His 435) in 
IgG, together with acidic residues in FcRn (Glu117, Glu132, Trp133, Glu135, and Asp137) 
provide an explanation for the strict pH dependence of the FcRn-IgG (or Fc) interaction (26). 
 
           The interaction of IgG with FcRn occurs in a mode distinct from that reported for T-
cell receptor-peptide-MHC class I interactions (45, 46), in which the T-cell receptor footprint 
covers the surface of the two MHC helices and binds antigenic peptide in a diagonal 
orientation. A ‘‘lying-down’’ model has been proposed for FcRn-IgG binding where an FcRn 
dimer binds to one IgG molecule. This is supported by in vitro studies showing that FcRn 
dimerizes upon binding to IgG in a higher afffinity (47). 
 
The interaction of FcγRs with IgG is different from FcRn 
         Mutagenesis studies indicate that the FcγR interaction sites of IgG are different from 
the region of IgG binding with FcRn. The residues in the lower hinge region of IgG are 
important for binding to FcγRI, FcγRIIa and FcγRIII (48-52). Other residues close to lower 
hinge spatially, such as FcγRI (Pro331) and FcγRII (Glu318), glycocylation of IgG are also 
important for FcγR binding(49, 53-55). The binding of both FcγRI and FcγRII to IgG was not 
inhibited by recombinant soluble FcRn, indicating that FcγR interaction site does not 





The FcRn-mediated transportation of IgG 
          FcRn, was initially identified as a receptor transporting maternal IgGs across placenta 
to the fetus and from the proximal small intestine to the newborn animals (36, 56). In other 
words, FcRn transcytoses IgG across a polarized cell layer from the mother to the offspring. 
In the gut of neonatal rodents, FcRn functions most efficiently in the neonatal period. 
Maternal IgG from ingested milk passes through the stomach, goes into the duodenum, 
where IgG binds to FcRn on the apical surface of an epithelial cell with the slightly acidic 
environment (57). The FcRn-IgG complexes are taken up by receptor-mediated endocytosis. 
The complexes are then transcytosed across the cells and delivered via exocytosis at the 
basolateral surface of the cells. FcRn then releases IgG into the underlying extracellular 
space, due to an increase in pH. In β2-microglobulin-/- or FcRn -/- mice, no maternal IgG 
was transported (58). These studies confirm that FcRn is the receptor involved in the 
transport of IgG from mother’s milk to newborns.  
        
          There is also a minor route for IgG transport in rodent. The successful cloning FcRn 
from rat yolk sac endoderm indicates that this Fc receptor is also involved in the maternal 
IgG transfer (59). However, the barely detectable FcRn on the cell surface led to the 
suggestion that FcRn binding to IgG occurs only after nonspecific uptake via fluid-phase 
pinocytosis by yolk sac.  
 
        In human, transporting maternal antibodies across placenta antenatally is the major route 
of IgG delivery to the fetus. Although the relative transfer efficiency of maternal IgG still 




syncytiotrophoblast internalizes fluid containing maternal IgG into endosomes; the IgG-
containing endosome is then gradually acidified thereby allowing IgG to bind tightly to FcRn 
present in this compartment. The vesicle then fuses with the membrane on the fetal side of 
the syncytiotrophoblast, where the physiological pH promotes the dissociation of IgG from 
FcRn. The FcRn molecule may then be recycled to the maternal membrane to perform 
additional rounds of transcytosis (57).  
 
          FcRn in human is different from that in rodents. In humans, FcRn is expressed by 
intestinal epithelial cells in both the fetus and adult (60, 61). However, intestinal expression 
of FcRn in rodent is highest on the epithelial cells of the proximal small intestine during the 
neonatal period and then decline rapidly after weaning. The level of FcRn in the intestine of 
adult rodent is very low (62, 63). The intestinal expression of FcRn in adult human suggests 
the additional role of FcRn besides the maternal IgG transfer. This hypothesis was proven by 
the study from Blumberg’s group. They showed that IgG–bacteria complexes were 
transcytosed across the epithelium by using a transgenic mice carrying human FcRn. FcRn in 
the mouse intestine delivered the immune complexes back to lamina-propria DCs, which 
then efficiently process and present antigen to the antigen-specific T‑cell in the draining 
lymph node (57). 
 
             Consistent with the observation that significant amount of IgG exist on the mucosal 
surface of lung, FcRn is highly expressed in the bronchiolar and alveolar epithelium in rats. 
Different from rat, FcRn is expressed predominantly in the upper airway epitheliumof 




taken for consideration seriously. FcRn is proposed to transport IgGs from the circulation to 
the lumen of lung airway, where IgGs provide protection against the pathogens from the air 
(64). Similarly, IgG absorption by the epithelium should not be ignored in these systems.  
   
FcRn-mediated IgG/albumin protection from catablism.          
         FcRn also acts as salvage receptors binding and protecting IgGs from lysosomal 
degradation. It has been demonstrated that the IgGs in both β2m and FcRn knockout (KO) 
mice have short serum half-lives (27, 58, 65-68). In FcRn-deficient mice, the serum IgG level 
is ~20–30% of wild-type animals, the half-lives of IgG and albumin are reduced from ~6–8 
days to ~1 day, similar to the typical half-life of other serum proteins that are not freely 
filtered by the kidneys (57). Consistent with these, other studies showed that a good 
correlation between affinity for binding IgG and serum half-life for IgG. The mechanism for 
FcRn-mediated IgG protection is likely through uptaken of IgG by cells expressing FcRn. 
Following entry into an acidic compartment such as endosome, IgG molecules bind to FcRn. 
Enzymes present in the vesicles downstream of endosomes, such as in lysosomes, digest 
unbound IgG; whereas, the IgG bound to FcRn is protected and recycled back out of the cells 
(69)(Fig. 1.2).  
           
           Recently, FcRn has also been shown to bind albumin and extend its half-life. In FcRn-
deficient mice, the serum albumin concentration is about 40% of the normal level. It is 
important to note that IgG and albumin make up ~90% of the protein content of serum. 
Therefore, through a pH-dependent binding, FcRn rescues IgG and albumin from 




            The exact tissure location of FcRn to protect serum IgG remains an open question, 
and the dual functions of FcRn also complicated this issue. At present, FcRn expressed on 
vascular endothelium is considered as the main player for IgG protection (70, 71). 
Expression of FcRn in the vascular endothelium of skeletal muscle and the skin in mice 
provides a large contact area for FcRn to contactwith blood (46, 71, 72). As these endothelial 
cells efficiently internalize serum proteins, FcRn is proposed to capture IgG and return it to 
the circulation, thereby prolonging the persistence of IgG in the serum. Alternatively, IgG 
may be saved from lysosomal catabolism when IgG is transcytosed into tissues through the 
polarized cells (57). 
 
          The expression of FcRn on monocytes, including MФs and DCs provides additional 
candidates for the IgG protection (73, 74).When WT bone marrow cells are adoptively 
transferred to FcRn deficient mouse, it  partially rescued the serum half-life of IgG (72). 
Most likely, myeloid-derived monocytes contribute to this protection by recycling the 
internalized IgG, as phagocytes and monocytes can ingest significant quantities of fluid.  
Additional functions for FcRn were found in professional antigen-presenting cells (APCs). 
The recent two reports describing the recycle of intact IgG immune complexes (ICs) in DCs 
and the impaired function of antigen presentation for ICs in FcRn -/- DC provide evidence 
for the divergent faces of FcRn (75, 76). 
 
FcRn, as therapeutic target for autoimmune diseases 
         As FcRn functions as salvager to maintain IgG homeostasis in the serum, and as 







































































































































































































































done in the IgG-mediated diseases by taking advantage of these characteristics of FcRn (57). 
In autoimmune diseases model (Table I.III), such as myasthenia gravis, bullous pemphigoid, 
idiopathic thrombocytopenic purpura (ITP) and systemic lupus erythematosus (SLE), the 
endogenously pathogenic IgG level was reduced by administration of high-dosage of 
intravenous immunoglobulins (IVIG) as a consequence of FcRn saturation (77, 78). Blocking 
FcRn-IgG interaction by using FcRn specific antibody is a more direct approach to reduce 
the titer of pathogenic IgG (78, 79). Alternatively, administration of humanized IgG 
monoclonal antibodies with Fc regions that bind to FcRn with an unusually high affinity 
results in the rapid degradation of non-bound endogenous antibodies (80). 
 
Transcriptional regualtion 
The nuclear factor-κB (NF-kB) and inhibitors of NF-kB (IkBs) 
          The mamalian NF-kB family has many members including RELA (p65), NF-kB1 
(p50; p105), NF-kB2 (p52; p100), c-REL and RELB (81, 82). These proteins have a 
structural conserved amino terminal region, which contains the dimerization, nuclear 
localization and DNA-binding domains. The RELA, RELB and c-REL also have a carboxy-
terminal domain which can activate transcription. The p50 and p52 is generated respectively 
from precursor p105 and p100 by proteolytic digestion, they lack transcription activation 
domain, but they still are able to bind to NF-kB consensus sites in DNA. Each member of 
NF-kB family can form homodimers as well as heterodimers with one another, except for 
RELB. The main activated form of NF-kB is the heterodimer of p65/p50 or p65/p52. p50 and 





         Table I.III   IgG-mediated autoimmune diseases 
 















Autoimmune haemolytic anaemia 
Idiopathic thrombocytopenic purpura 
Rheumatoid arthritis 
Scleroderma 

















restricted to thymus, lymph nodes and Peyer’s patches. The c-REL is confined to 
haematopoietic cells and lymphocytes (81, 83). 
 
             It has been well documented that the association of IkBs with NF-kB proteins in the 
cytoplasm results in the inactivation of NF-kB. Most commonly, IkBs are composed of 
IkBα, IkBβ and IkBε, which are defined by the presence of ankyrin repeats, a 33-amino-acid 
motif that mediates protein-protein interactions. Another unusual member of IkBs is BCL-3, 
which specifically interacts with p50 or p52 homodimers and can enhance the NF-kB-
regulated genes. This is in contrast to the inhibitory function of IkBs (83). The subsequent 
phosphorylation, ubiquitination and proteasome-mediated degradation of IkBs result in the 
liberation of NF-kB heterodimers follwed by rapid translocation to the nucleus. IkBs are 
phosphorylated by IkB kinases (IKKs) including IKKα, IKKβ and IKKγ. IKKs mediate site-
specific phosphorylation of the IkBs, which triggers the degradation of NF-kB inhibitors. 
Once in the nucleus, NF-kB bind to the consensus sequence (5’-GGGRNYYYCC-3’, R: 
purine, Y: pyrimidine, N: any nucleic acid) and activate gene transcription (84).  
 
NF-κB signalling pathways through TLR ligands and cytokines 
          The NF-kB/REL family of transcriptional factors has an essential role in regulating the 
expression of a wide variety of genes that control both innate and adaptive immune response. 
NF-kB is activated rapidly in response to a wide range of stimuli, including pathogens, stress, 
and inflammatory cytokines. Many pathogens are recognized by specific pathogen-
recognition receptors (PRR). These pathogens are consistently found bearing small molecular 




lipopolysaccharide (LPS), peptidylglycans, lipoproteins, unmethylated bacterial DNA and 
double strand RNA are considered as PAMPs. The best known PRRs are Toll-like receptors 
(TLRs), a group of transmembrane proteins that mediates the intracellular signalling after 
recognizing the extracellular pathogens. The binding of PAMPs with TLRs will activate an 
intracellular signaling cascade through TLR cytoplamsic Toll/IL-1 receptor (TIR)-homology 
domain. The TLR family signaling pathway is highly homologous to that of IL-1 receptor 
(IL-1R) family in mammals. Both TLR and IL-1R interact with an adaptor protein MyD88 
(myeloid differentiation primary response gene 88). Upon stimulation, MyD88 recruits IL-1R 
associated Kinase (IRAK), IRAK is activated by phosphorylation and then associates with 
TRAF6 (TNF receptor associated factor 6), leading to activation of NF-kB (85). The 
complex of transforming-growth-factor-β-activated kinase 1 (TAK1), TAK-binding protein 
(TAB1) and TAB2 was considered as an integral component that linked TRAF6 and 
downstream IKK complexes, but recent observation from TAB1-andTAB2-knockout mice 
did not support the roles for these proteins in NF-kB signalling (83). Another candidate 
molecule that links TRAF6 and NF-kB was identified in a screen of TRAF6-interacting 
molecules, designated ECSIT (evolutionarily conserved signaling intermediate in Toll 
pathways), and the roles for ECSIT need more studies (86, 87). 
 
           Cytokines, such as TNF and IL-1, are another important class of NF-kB inducers. 
TNF and IL-1 activate signaling cascade that lead to the activation of activitor protein1 
(AP1) and NF-kB, which regulates the expression of inflammatory cytokine genes. IL-1 
activates NF-kB in a similar manner to LPS, because both IL-1R and TLR 4 contain 




results in the receptor trimerization and recruitment of adaptor protein TRADD (TNF 
receptor-associated via death domain) to the cytoplamic tail. TRADD interacts with carboxyl 
terminus of TRAF2. Mitogen-activated protein (MAP)/extracellular signal-regulated kinase 
ERK) kinase kinase 3 (MEKK3) and receptor interacting serine/throenine kinase (RIP) are 
likely to relay the signal from TNF to IKKs (88, 89). 
 
JAKs ( Janus family tyrosine kinases)-STATs (Signal transducer and activitor of 
transcription) 
        JAKs and STATs pathway is integral to both type I (IFN-α/β) and type II (IFN-γ) 
interferons and to all type I cytokines which share a similar four-α-helix bundle strutures. 
This pathway represents a rapid membrane-to-nucleus signaling system to induce many 
important biological responses in the target cell (90). 
         
            Jaks are relatively large kinases of approximately 1150 amino acids with molecular 
weight 120-130 kDa. Jak family is recognized by the existance of tandem kinases domain 
(JH1) and pseudokinase domains (JH2) in the C-terminal. In addition, five other Jak 
homology (JH3-JH7) domains were defined in Jaks. The N-terminal of Jaks seems to 
associate with receptor subunits.  Four Jaks have been identified in mamalian: Jak1, Jak2, 
Jak3 and Tyk2 (Tyrosine kinase 2). The essential functions of Jaks are established in many 
cytokine signaling pathways. Specially, IFN-α/β requires Jak1 and Tyk2, whereas IFN-γ 
requires Jak1 and Jak2 (91).  
            




Stat6 and Stat7. STATs are approximately 750-850 amino acids in length. They have a 
conserved tyrosine (~700 residues), whose phosphorylation allows STATs dimerization, a 
Src homology (SH2) domain and an N-terminal domain known to play a role in the 
dimerization of STATs, and the DNA binding domain located in the middle region (91). 
Following the interferons binding to their receptors, Jak kinase is rapidly induced and 
phosphorylates the interferon receptors. Such phosphorylation provides docking sites for 
STATs. The recruited STATs are phosphorylated, dimerized and released from the receptors. 
The dimric form then translocates into the nucleus and binds with STATs binding sites to 
mediate gene expression. 
           
           Interferons have potent antiviral and growth inhibitory effects, which provide the first 
line in defence against viral invasion and have important roles in immunosurveilance for 
malignant cells. The binding of type I interferons (mainly IFN-α/β) with their receptors 
(IFNAR1 and IFNAR2) results in the phosphorylation and activation of Jak1 and Tyk2. 
Activated Jak1 and Tyk2 in turn regulate the phosphorylation and activation of Stat1 and 
Stat2. Together with IRF-9 (Interferon-regulatory factor 9), the dimerized Stat1 and Stat2 is 
delivered to the nuclues and binds to specific elements known as interferon-stimulated 
response element (IRES), thereby initate the gene expression (90, 92). Other Stats, such as 
Stat3, Stat5, Stat4 and Stat5 can also be activated by type I interferon. In contrast, the 
association of type II interferon (IFN-γ) with its receptor (IFNGR1 and IFNGRII) triggers 
activation of Jak1 and Jak2, which induce the phosphorylation of Stat1. Phosphorylated Stat1 
forms homodimer, translocates into the nucleus and binds to GAS sites (Interferon-γ-




            
            The phosphorylation of tyrosine residues (Tyr 701) in STATs by JAKs is a crucial 
step in IFN-mediating sigaling, as it is required for the dimerization and translocation of 
STATs (93). However, in Stat1 and Stat3, serine residue at position 727 (Ser 727) is also 
found phosphorylated by the induction of type I and type II interferons. The Ser727 is located 
in the C-terminal domain. Such phosphorylation is not required for their translocation, but it 
is essential for full transcriptional activaties (94, 95).  
            
             IFN-activated STATs can interact with other proteins to enhance the transcriptional 
precisement. For examples, the protein inhibitor of activated STAT-1 (PIAS1) and 
suppressor of cytokine signaling (SOCS) have been shown to negatively regulate STAT-1 
signaling in cytosol (96). The association of STATs with p300 and CBP (cAMP-responsive 
elements-binding protein (CREB) binding protein) in nucleus increase IFN-α- or IFN-γ- 
inducible transcription. P300 and CBP are acetyltransferases which remodel the chromatin 
and regulate the gene expression on epigenic level (97). 
 
Antigen presentation 
MHC class I-restricted antigen presentation.  
       Endogenous proteins destined to presentation on MHC-I molecules are ubiquitinated in 
cytosol and degradated by proteasome. The resulting peptides are transferred to the ER by 
TAP (Transporter associated protein) and loaded on the newly synthesized MHC-I molecules 
under the help of loading complex comprised of several chaperones (tapasin, calnexin, and 




Golgi apparatus to the plasma membrane, where MHC-I molecules interact with TCR of 
CD8+ T cells and activate CD8+ T cells. The sources for endogenous proteins vary, incuding 
cytosolic proteins, alternative translation products and defective ribosomal translation, 
proteins retranslocated to the cytosol from ER, and internalized proteins transferred to the 
cytosol (99). 
 
            Exogenous proteins can also be presented on MHC-I molecules, a recently discribed 
antigen presentation route denoted as “Cross-presentation”. Exogenous proteins are 
internalized by various ways. Macropinocytosis allows the soluble antigen cross-presented in 
DCs. Phagocytosis has been shown a major route for antigen uptake and cross-presentation in 
both MΦ and DC. Interestingly, phagocytosis of apoptosic cells also results in efficient cross-
presentation of viral and tumor antigens. In addition, FcR-mediated uptake of immune 
complexes enhances the cross presentation efficiently. The MHC class I peptide loading for 
cross presentation occurs at two main sites, either endocytic compartment or ER lumen. 
Endocytic compartments pathway is sensitive to proteases inhibitors and TAP-independent, 
this requires the presence of MHC-I molecules in the endocytic compartments. By contrast, 
ER lumen pathway is sensitive to proteasome inhibitor and requires TAP, and the antigen 
transport pathway from endocytic lumen to cytosol is essentially required for TAP-dependent 
cross presentation.  
 
MHC class II-restricted antigen presentation 
             Antigens loading on MHC class II molecules occur through a different pathway 




chains (Ii). Ii chain will escort MHC-II from ER to the endocytic pathways under the tranport 
signal present in the cytoplasmic tail of Ii chain. Once in the endosomes and lysosomes, the 
acidic environment facilitates proteolytic enzyme to digest Ii chain. MHC-II dimers become 
competent to bind antigenic peptide under the control of two nonpolymorphic MHC-II 
molecules HLA-DM/HLA-DO (human). MHC-II peptide complexes reach to the plasma 
surface after peptide loading onto the MHC-II molecules. Antigen loaded onto MHC-II 
molecules are typically generated from exogenous proteins internalized by antigen presenting 
cells (APC). The internalization of exogenous proteins is mainly through four pathways, 
including phagocytosis, micropinocytosis, clathrin-meditaed endocytosis and non clathrin 
endocytosis. 
 
Macrophage and DC 
         MΦ has long been considered the prototypical APC, simply due to the fact that they are 
associated with microoganisms endocytosis in innate immune response. MΦ owns 
extraordinary capacity for endocytosis. It can internalize cell-associated or soluble antigens, 
either nonspecifically or via specific receptors (FcR, lectins, etc.), allowing them to stimulate 
T cells. MΦ express MHC-I, MHC-II, and costimulatory molecules, and their expression 
level can be upregulated by the stimulation of inflammatory cytokines or bacterial products. 
Although the level of MHC II and costimulators expressed on MΦ are lower than that of DCs 
and B cells. the large number of MΦ at the sites of infection and chronic inflammation  






            DCs are the most efficient antigen-presenting cells to the T cell stimulation. Both MΦ 
and DCs are originated from bone marrow-derived precursor and take residence in peripheral 
tissue. Nearly all the tissues contain MΦ and DCs, but the primary function for DCs is 
antigen presentation. DCs exhibit a variety of features that greatly enhance the capacity as 
APCs. First, DCs have unique surveillance and migratory properties to carry antigen acquired 
in the periphery to lymph node and then activate the naïve T cells . Second, DCs can 
endocytose and present virtually any form of protein antigen on MHC I and II molecules. 
Third, exceptionally high level of MHC-II and co-stimulatory molecule is expressed on DCs.  
Fourth, DCs own the capacity to tightly control the antigen degradation (99).  
 
          The function of DCs can be regulated by maturation, and the maturation induces a 
dramatic structural reorganization. Immature DCs express low levels of surface MHC II and 
co-stimulatory molecules, together with high capacity of endocytosis. Upon stimulation by 
TLR ligand, inflammatory cytokines, DCs begin to mature with several changing features. 
First, MHC II is transported to the plasma membrane associated with high levels of 
costimulatory molecules (100, 101). Second, endocytosis rates decrease dramatically 
following a transient increase (102). Finally, DCs change the morphology with extended 
dendrites and more folded membrane. Concomitant with these features, DCs switch the 
function from antigen handling to T cell activation (100). 
 
           QUESTIONS TO BE ADDRESSED IN MY PROJECT 
          In our study, we want to know whether FcRn can be regulated in the context of 




FcRn can be regulated by inflammatory cytokines, toll-like receptor ligands, and interferons. 
This will be described in detail in Chapter 2 and Chaper 3. Furthermore, the phagosomal 
pH difference in DC and MФ leads to a new discovery of FcRn-mediated antigen 
presentation of immune complexes (Chapter 4). 
 
 




CHAPTER 2: NF-κB SIGNALING REGULATES FUNCTIONAL 
EXPRESSION OF FcRn VIA INTRONIC BINDING SEQUENCES 
  
 ABSTRCT  
            The neonatal Fc Receptor for IgG (FcRn) functions to transport maternal IgG to 
a fetus or newborn and to protect IgG from degradation. Although FcRn is expressed 
in a variety of tissues and cell types, the extent to which FcRn expression is regulated 
by immunological and inflammatory events remains unknown. Stimulation of 
intestinal epithelial cell lines, macrophage-like THP-1, and freshly-isolated human 
monocytes with cytokine tumor necrosis factor-α (TNF-α) rapidly up-regulated FcRn 
gene expression. In addition, Toll-like receptor ligands lipopolysaccharides and CpG-
oligodeoxynucleotide enhanced the level of FcRn expression in macrophage-like 
THP-1 and freshly-isolated human monocytes. Treatment of TNF-stimulated THP-1 
cells with nuclear factor-kappa B (NF-κB) specific inhibitor, or over-expression of a 
dominant negative mutant inhibitory nuclear factor-kappa B (IκBα, S32A/S36A) 
resulted in down-regulation of FcRn expression. By chromatin immunoprecipitation, 
we identified three NF-κB binding sites within introns 2 and 4 of the human FcRn 
gene. The intronic NF-κB sequences in combination with the promoter or alone 
regulated the expression of a luciferase reporter gene in response to TNF-α 
stimulation or over-expression of NF-κB p65 and p50. DNA looping interactions 
potentially occurred after the stimulation between intronic NF-κB sequences and 




these data provide the first evidence that NF-κB signaling via intronic sequences 




           The neonatal Fc receptor for IgG (FcRn) differs from FcγRs because it is 
structurally related to the MHC class I family, with a membrane-bound heavy chain 
(HC) in nonconvalent association with β2-microglobulin (β2m) (26, 47). The overall 
exon-intron organization of the FcRn gene is similar to that of MHC class I 
molecules, with the exception of a very large 10-kb intron between exons 4 and 5. In 
addition, FcRn displays pH-dependent binding of IgG; specifically, FcRn 
preferentially binds IgG at acidic pH (6-6.5) and releases it at neutral pH (7-7.4).  
FcRn is a transport receptor involved in controlling the movement of IgG from the 
maternal to the fetal blood of rodents and humans in placental and/or intestinal 
tissues. FcRn, therefore, plays a major role in the passive acquisition of neonatal 
immunity to newborn mammals. FcRn also functions in the maintenance of IgG 
homeostasis in mammals of all ages by salvaging IgG from degradation. In the 
proposed model, IgG is taken up into cells by pinocytosis or endocytosis from the 
surrounding tissue fluid or blood. FcRn in acidic compartments, such as the 
endosome, binds and recycles IgG out of the cell to avoid IgG degradation in the 
lysosome. The IgG transport and protective functions of FcRn are evidenced by 
several studies in which mice deficient in either β2m or the FcRn HC fail to transport 






            Although first observed in the intestinal epithelial cells of the neonatal rodent, 
FcRn has more recently been shown to express in a variety of cell types and tissues, 
including epithelial cells, endothelial cells, macrophages and dendritic cells in adult 
life (73). The level of FcRn expression appears to be critical for controlling IgG 
levels in tissues and blood (106). In autoimmune situations, FcRn expression may act 
as a rheostat that enables sufficient levels of pathogenic IgG to permit downstream 
conventional FcγR-mediated immune responses, immune complexes and 
inflammatory cascades. Indeed, FcRn has been shown to be associated with the 
development of pathogenic IgG-mediated autoimmune diseases (107, 108)). Although 
an understanding of the operative mechanism of FcRn function is emerging, evidence 
of how FcRn is regulated, especially under immune responses or inflammatory 
reactions, is not understood. The central roles that FcRn plays in the protection and 
transportation of IgG under normal or inflammatory situations have led to an 
increased interest in the mechanism that controls FcRn expression with regard to both 
the constitutive and stimuli-mediated receptor expression. 
 
           Nuclear factor kappa B (NF-κB) is a family of transcription factors that 
coordinate the expression of numerous genes in the innate and adaptive immune 
responses and development of inflammatory and autoimmune diseases. NF-κB is 
composed of five members of the Rel family, including NF-κB1 (p50), NF-κB2 (p52), 
RelA (p65), RelB, and c-Rel (Rel) (83). These proteins form homo- and heterodimers, 




interactions with specific inhibition proteins known as IκBs. Upon stimulation, 
signals that induce NF-κB activity subsequently cause the phosphorylation of IκBs by 
IκB kinase complex. As a result, ubiquitin ligase complex interacts with the 
phosphorylated IκB, mediates poly-ubiquitination of IκB, and leads to its subsequent 
proteasomal degradation (109, 110) . The degradation of IκB proteins, thereby, 
allows NF-κB dimers to translocate to the nucleus and bind cognate NF-κB 
sequences of target genes.  
 
          In the present study, we investigate the involvement of NF-κB activation in the 
regulation of human FcRn expression and function. Our study showed that NF-κB 
specific inhibitor significantly down-regulated expression of human FcRn gene. 
Using several complementary strategies, we have further identified direct 
involvement of NF-κB specific binding sites located in human FcRn introns 2 and 4  
that may function as modulators that are responsive to immunologic and 




MATERIALS AND METHODS 
Cell lines, antibodies, reagents 
           Human intestinal epithelial cell lines HT-29 and Caco-2, and THP-1 cells 
(kind gifts from Dr. Richard S. Blumberg, Harvard Medical School, Boston, MA) 




with 10 mM HEPES, 10% fetal calf serum, L-glutamine (1:100 dilution), nonessential 
amino acids, and penicillin/streptomycin (1:100 dilution) in a humidified atmosphere 
of 5% CO2 incubator at 37°C.  
 
           The anti-human FcRn monoclonal antibodies DVN24 and ADM31 were made 
by immunizing C57BL/6 mFcRn -/- mice first with 2x107 spleen cells from C57BL/6 
human FcRn transgenic mice in complete Freund’s adjuvant (Sigma, St Louis, Mo), 
followed 2 weeks later with the same cells in incomplete Freund’s adjuvant (Sigma). 
Spleen cells from seropositive responder mice were fused with SP2-0 cells using 
established procedures to make hybridomas.  HRP-conjugated donkey anti-rabbit 
antibody was purchased from Pierce (Rockford, IL), and purified human IgG from 
Jackson ImmunoResearch Laboratories (West Grove, PA). Antibodies against NF-κB 
p65, p50, Rel B, p52 were obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA), and IL-1β and TNF-α from R&D Systems (Minneapolis, MN). Affinity-purified 
rabbit anti-FcRn antibody has been described (9). Phosphorothionate CpG ODN (5′-
TCGTCGTTTTGTCGTTTTGTCGTT-3′) and mutant GpC ODN (5′-
TCTGGCTTTTCTCATTTTCTGGTT-3′) were from Operon (San Francisco, CA).  
Semi-quantitative RT-PCR and quantitative real-time RT-PCR 
Total RNA was isolated from cells (2 x 106/ml) in TRIzol (Invitrogen). cDNA was 
generated by amplification of total RNA using the FcRn-specific primers 
(5’CCGGAATTGGAGCCCCCCTCCAT-3’, 5’-
TGCTCTAGAGGAGGACTTGGCTGGAGATT-3’) with a one-step RT-PCR kit 




5’-TGCTGATGATCTTGAGGCTG-3’). Thirty cycles of PCR amplification were 
performed under optimized conditions. The total RNA samples were extracted from 
freshly-isolated human CD14+ CD11+ monocytes (Cambrex, Baltimore, MD). The 
106 cells/ml monocytes were stimulated with TNF-α (50 ng/ml) or LPS (1μg/ml). 
Total RNA (150 ng/reaction) was reversely transcribed to yield first-strand cDNA 
using Superscript III (Invitrogen). Real-time RT-PCR was performed using FcRn and 
GAPDH primers and the SYBR Green Supermix Kit (Bio-Rad) in Chromo 4 (MJ 
Research, MA). FcRn expression was calculated following normalization to GAPDH 
levels by the comparative delta delta CT method. All reactions were performed for 40 
cycles: 15 s at 94°C, 15 s at 58°C, and 20 s at 72°C. The specificity of the 
amplification reactions was confirmed by melt curve analysis. Software Opticon 
Moniter 3.1 was used for real time RT-PCR.   
 
Gel electrophoresis, Western blot, and IgG binding assay  
          Gel electrophoresis and Western blots were performed as previously described 
(108, 111). In brief, cell lysates were prepared in PBS with 0.5% CHAPS by adding a 
protease inhibitor cocktail (Sigma, St. Louis). A post-nuclear supernatant was 
analyzed for total protein concentrations by the Bradford method with BSA as a 
standard (BioRad, Hercules, CA). The proteins were separated on 12% SDS-PAGE 
gels under reducing conditions and transferred onto nitrocellulose (Schleicher & 
Schuell, Keene, NH). The membranes were blocked with 5% non-fat milk and probed 
with affinity-purified anti-human FcRn antibody, then with HRP-conjugated Goat 




containing 0.05% Tween-20. The final product was visualized by ECL (Pierce, 
Rockford, IL). 
  
             IgG binding assay was performed as previously described (20). Cells were 
lysed in PBS (pH 6.0 or 7.5) with 0.5% CHAPS (Sigma) and protease inhibitor 
cocktail. Post-nuclear supernatants containing 0.5–1 mg of soluble proteins were 
incubated with human IgG-Sepharose (Amersham Pharmacia Biotech). The unbound 
proteins were washed away with PBS (pH 6.0 or 7.5) containing 0.1% CHAPS. The 
adsorbed proteins were boiled with reducing electrophoresis sample buffer. The eluted 
proteins were subjected to 12% SDS-PAGE gel electrophoresis. Proteins were 
visualized by Western blot. 
 
Chromatin immunoprecipitation (ChIP) 
           ChIP experiments were performed according to the manufacturer 
recommendations (Upstate Biotechnology Inc, Lake Placid, NY). In brief, THP-1 
cells (5 x 106 cells) were incubated with or without TNF-α (50 ng/ml) for 20-60 min. 
The cells were fixed with formaldehyde. The nuclei were isolated and sonicated. 
Chromatin was immunoprecipitated overnight at 4°C by mild agitation with 5 µg of 
antibody specific for p65, p50, or with 5 µg of normal IgG as negative control. 
Immune complexes were collected by incubation with protein-A-agarose. The DNA 
samples were amplified by PCR primers in an optimized condition.  
  




             The pLUC-MCSFcRn vectors were constructed by cloning the pairs of 
complementary oligonucleotides encompassing the three tandem NF-κB binding 
sequences from the FcRn introns (Fig. 2.4 A, +1104, +5561, +9651). An FcRn DNA 
sequence (+3463) was also used as negative control. Double-stranded oligonucleotide 
was cloned into the pLUC-MCS plasmid (Stratagene, La Jolla, CA) digested with 
Hind III and Xho I. All plasmids were verified by DNA sequencing analysis.  
  
Transient transfection and Luciferase assay 
            THP-1 and HT-29 cells were transiently transfected with Effectene (Qiagen, 
Valencia, CA). In each co-transfection, 2 × 106 cells were transfected with a DNA 
mix containing 0.95µg firefly luciferase reporter plasmid and 0.05 µg Renilla 
luciferase pRL-TK control plasmid. In the following day, the cells were cultured with 
or without TNF-α (10-50 ng/ml). The cells were harvested 24 hr after stimulation and 
assayed for the expression of renilla and firefly luciferase using the dual luciferase kit 
(Promega, Madison, WI). The values for firefly luciferase were normalized to the 
renilla luciferase activity and expressed as fold activation over the vector background.  
 
 Chromosome conformation capture (3C) assay  
             The 3C experiment was modified according to previously-described 
procedures (112, 113). Briefly, THP-1 cells (1 X 107) were fixed with 2% 
formaldehyde. The nuclei were harvested and suspended in the Hind III digestion 
buffer containing 0.3% SDS at 37°C for 1 hr. Triton X-100 was added to a 1.8% final 




37°C. Samples were then diluted with ligase buffer. Trinton X-100 was added to a 
final concentration of 1%. T4 DNA ligase was then added for incubation at 16°C for 
4.5 hr. The intramolecular ligation of cross-linked fragments was optimized, and 
ligation product was monitored by PCR. Proteinase K was added at 200 µg/ml final 
concentration. The samples were incubated at 65°C overnight to reverse cross-linking 
and the DNA was isolated. 
 
             The PCR amplifications were determined by primer pairs in Table II.I. Primer 
pairs were designed to span each of six Hind III sites positioned along the 15-kb 
region of the human FcRn gene. Primers were used for cross-linked and control 
templates in all pairwise combinations. In general, DNA amplifications were done in 
20-µl reaction mixtures by an initial denaturing step for 5 min at 94 °C, then 35 
cycles of PCR. PCR products were cloned and sequenced to confirm the presence of 
the FcRn DNA fragments ligated in a Hind III site.  
 
RESULTS 
Up-Regulation of FcRn expression by TNF-α  
           The NF-κB is well known to be activated by exposure of cells to 
proinflammatory mediators, such as TNF-α  (114). To show the possibility that TNF-
α regulate the gene expression of human FcRn, we treated human freshly isolated 
monocytes treated with TNF-α (50 ng/ml),  FcRn mRNA was increased 12-fold over 
the mock-stimulated cell after 20 min and about 17-fold after 1 hr, as assessed by real 




including transcription factors, are required for TNF-dependent induction of FcRn 
mRNA, we treated THP-1 cells with cycloheximide (CHX, 25 μg/ml) and then 
subsequently with cytokines for 20 minutes and 1 hr. CHX failed to inhibit the TNF-
α-dependent induction of FcRn expression from both semi-quantitative or real time 
RT-PCR.These data indicate that de-novo protein biosynthesis was not required for 
the induction of FcRn transcription by TNF-α. The enhanced expression of FcRn 
protein in THP-1 cells was shown by Western blot in TNF-α-stimulated cells 
(Fig.2.1B, lanes 4-5) in comparison with mock-stimulated cells (lane 3). Lysates from 
Hela and Hela-FcRn were used as a negative (Fig 2.1 B lane 1) and positive (lane 2) 
controls in Western blot. Furthermore, induction of FcRn protein could be 
significantly detected by staining with flow cytometry or immunofluorence 
microscope with FcRn-specific antibodies in THP-1 cells.  
  
                 FcRn binds IgG at acidic pH 6.0 and releases IgG at neutral pH (27). We 
tested whether the enhanced expression of FcRn after TNF-α stimulation affects its 
ability to bind to its natural ligand IgG. We incubated cell lysates from cells at either 
pH 6.0 or pH 8.0 with human IgG-Sepharose. Cell lysates from Hela cells transfected 
with FcRn were used as positive control. As expected, FcRn from Hela-FcRn cells 
bound IgG at pH 6.0, but not pH 8.0 (Fig. 2.1 C, lanes 5-6). Our result showed that 
TNF-α stimulation enhanced cellular FcRn binding to IgG at pH 6.0 (Fig. 2.1C, lane 
3) in comparison with mock-stimulated cells (Fig. 2.1C, lanes 1), suggesting the 
enhanced level of FcRn led to increased FcRn-IgG complexes. To evaluate other cell 




TNF-α (10 ng/ml). The mRNA level of FcRn was increased about 2.5-fold over the 
unstimulated level (Fig. 2.1 D).  
 
Regulation of FcRn expression in THP-1 cells by a TLR-mediated signaling 
pathway 
      Similar to TNF-α receptor engagement, activation of Toll-like receptors (TLR) by 
their cognate ligands can effectively result in NF-κB activation (115). We 
investigated the activation of TLR on cells in the induction of human FcRn 
expression. The TLR9 binds nonmethylated CpG-containing DNA and the TLR4 in 
association with CD14 recognizes ligand LPS. THP-1 cells express both TLR4 and 
TLR9 (115). FcRn mRNA appeared to be rapidly augmented in response to CpG in 
comparison to the mutant GpC treatment (Fig. 2.2 A). CpG increased the FcRn 
mRNA level 1.7-fold and 2-fold over the unstimulated cell after 60 and 120 min,  
   respectively. THP-1 cells expressed nearly undetectable levels of CD14 expression on 
the surface. The phorbol 12-myristate 13-acetate (PMA) and 1,25-dihydroxy vitamin 
D3 are known to increase the expression of CD14 (116). Thus, THP-1 cells were first 
stimulated with 100 nM PMA and 100 nM 1,25-dihydroxy vitamin D3. THP-1 cells 
were then mock-treated (Fig. 2.2 B, lane 1) or treated by LPS (1μg/ml) (Fig. 2.2 B, 
enhanced 1.8 fold after 1 hr (lane 3) and up to 2-fold after 3 hr (lane 5) following 
LPS stimulation. Furthermore, human freshly isolated monocytes treated with 
LPS (1 µg/ml) increased FcRn mRNA level 6-fold over the mock-stimulated cells 















 lanes 2-5). Semi-quantitative RT-PCR showed that the FcRn mRNA level was  
 
Figure 2.1  FcRn expression in response to cytokine stimulation. A. Quantitative real-time 
RT-PCR analysis of FcRn mRNA in freshly isolated human monocytes treated with TNF-α (50 
ng/ml) for indicated time or mock treated. B. Western blot. The cell lysates (10 μg)  from Hela (lane 
1), Hela-FcRn (lane 2),  TNF-stimulated THP-1 (lanes 3-5) was blotted with FcRn- (top panel) or β-
actin- (bottom panel) specific antibody (bottom panel). The ratio of the mock group is assigned a 
value of 1.0, and the values from other groups are normalized to this value. C. The pH-dependent 
FcRn binding of IgG. D. Quantitative real-time RT-PCR analysis of FcRn mRNA by analyzing total 
RNA extracted from HT-29 cells treated with TNF-α (10 ng/ml) as indicated time.  Data are mean ± 





 the studies in Fig. 2 suggest that activation of TLR signal pathways, similar to TNF- 
and IL-1β, can also enhance FcRn expression. 
 
Effect of NF-κB inhibition on FcRn expression 
             Because downstream activation of TNF-α, IL-1β, and Toll-like receptors 
undergoes the similar NF-κB-mediated signaling pathway, we further study the 
function of NF-κB signaling in FcRn transcription.  Several steps of the NF-κB 
activation pathway, such as IκB kinase activation, IκB phosphorylation and 
degradation, and NF-κB nuclear translocation, can be targeted by a variety of 
inhibitors (117). Caffeic acid phenethyl ester (CAPE) has an inhibitory effect on the 
translocation of NF-κB p65 to the nucleus and inhibition of NF-κB binding to DNA 
(117). THP-1 cells were pretreated with CAPE (25 μg/ml) for 2 hr, subsequently 
stimulated by TNF-α. Treatment with CAPE significantly reduced TNF-α-stimulated 
   FcRn levels to that of the mock-stimulated THP-1, as assessed by semi-quantitative 
RT-PCR (Fig. 2.3 A). We further tested the effects of CAPE on CpG-stimulated 
THP-1 cells, and similar inhibitions were observed. Treatment with CAPE 
significantly reduced CpG-stimulated FcRn yield to the level of the mutant GpC-
stimulated THP-1. In addition, CAPE did not exert the obvious toxicity to cells in our 
assay. 
 
        NF-κB can be activated by phosphorylation of its inhibitory subunit, IκB-α, 
on serine residues 32 and 36 by IκB kinases (109). Signaling through the TNF-α or 




















              
   
   
Figure 2.2 FcRn expression in response to CpG or LPS stimulation. 
A.THP-1 cells were stimulated with 4 μg/ml CpG or mutant GpC for 60 and 120 min. A representative 
sample for RT-PCR analysis using total RNA extracted from the cells is shown for FcRn and GAPDH. 
B. THP-1 cells were pretreated with PMA and 1,25-dihydroxy vitamin D3 for 6 days, then  
stimulated with 1 μg/ml LPS for the indicated time. A representative sample for RT-PCR analysis 
using total RNA extracted from the cells is shown for FcRn and GAPDH. C.Quantitative real-
time RT-PCR analysis of FcRn mRNA from freshly isolated human monocytes treated with 
LPS (1 µg/ml) for the indicated times or left untreated. Data are mean ± SD of three 





   residues for serines 32 and 36 within the N-terminal signal response domain can 
abolish the signal-induced IκBα phosphorylation and ubiquitination for degradation, 
resulting in a blockage of NF-κB activation. Over-expression of this IκBα 
(S32A/S36A) decreased FcRn expression in response to TNF-α by at least 80% (Fig. 
2.3 B, lane 3), compared to cells transfected with a control plasmid (Fig. 2.3 B, lanes 
1 and 2). Overall, this selective NF-κB inhibition by CAPE in conjunction with the 
over-expression of dominant IκB mutant indicates that the blockade of NF-κB 
activation inhibited the FcRn transcription in response to TNF-α.  
 
Screening for NF-κB binding sites adjacent to the FcRn gene 
         The canonic NF-κB DNA binding sequence is a common 10-bp consensus DNA 
element, which has been identified as 5’-GGGRNNYYCC-3’ or 5’-
HGGARNYYCC-3’ (where H is A, C, or T; R is an A or G purine; and Y is a C or T 
   pyrimidine) (83). We hypothesized that NF-κB regulates FcRn expression through a 
mechanism that involves direct binding to a putative regulatory NF-κB binding 
sequence (s) located in the FcRn gene. To test this hypothesis, we searched for 
   putative NF-κB-binding sequence (s) along the entire human FcRn genomic sequence 
(Fig. 2.4 A) (GenBank accession No. AC010619). Computational inspection revealed 
   that the promoter and introns of FcRn gene contained sequences with a similarity to 
   the NF-κB consensus sequence (Fig 2.4 B). To verify that these putative NF-κB 
binding sequences do have the capability to directly bind NF-κB proteins in living 
cells, we employed a ChIP assay to precipitate the NF-κB-DNA complexes with 










Figure 2.3 Effect of NF-κB inhibitors on the expression of FcRn. A  Effects of CAPE on 
expression of FcRn mRNA. B. Effect of NF-κB blockage by IκBα on expression of FcRn. Human 
THP-1 cells were transfected with the dominant-negative construct pCMV-IκBα (S32A/S36A). 
















   proteins in situ in TNF-stimulated verus unstimulated THP-1 cells. The DNA 
fragments containing the putative NF-κB binding sequences in FcRn gene were 
measured by PCR. As shown in Fig. 2.4 C, PCR with primers flanking the putative 
NF-κB binding sequences (Fig 2.4 C, +1104, +5561, +9651) produced a band from 
DNA coprecipitated with p65 or p50. In a negative control, immunoprecipitation with 
normal rabbit IgG did not generate any corresponding PCR products (Fig 2.4 C, lane 
6). The NF-κB binding sequence in the IκB gene promoter was used as a positive 
control. These data suggest that NF-κB p65 and p50 interacted with the three NF-κB 
binding sequences of FcRn gene in THP-1 cells.  
 
NF-κB binding sequences in FcRn introns can regulate the expression of the 
luciferase  
          We constructed luciferase reporter plasmid in which three tandem copies of 
NF-κB binding sequences (+1104, +5561, +9651) were respectively linked to a  
   minimal promoter containing only a TATA box (Fig. 2.5 A). The pLuc-MCS 
plasmids (Fig. 2.5 A) were transiently transfected into intestinal HT-29 cells with or 
without co-transfection of the NF-κB p50/p65 plasmid in order to validate the results  
   obtained from THP-1 cells. The data showed that each NF-κB binding sequence 
significantly amplified the luciferase signal from 2-12 folds in cooperation with 
p65/p50 proteins (Fig. 2.5 B). A relevant DNA sequence (Fig. 2.4 B) that did not bind 
p50 or p65 in vivo from our ChIP assay was used a negative control, and it failed to 
enhance the luciferase activity over vector alone (Fig. 2.5 B). However, NF-κB 
















Figure 2.4 Mapping of NF-κB binding sequence (s) in human FcRn gene by 
chromatin immunoprecipitation (ChIP). A. Organization of the human FcRn gene. 
Arrowheads indicate the position of candidate NF-κB sequences. Exons (E) are drawn as 
boxes and intron numbers are shown as Roman numerals. B. The putative NF-κB binding 
sequences in FcRn gene are listed. Numbers represent the putative NF-κB binding sequences 
relevant to the transcription start site of the FcRn gene. The consensus NF-kB sequence is 
bolded. R is an A or G purine; and Y is a C or T pyrimidine. C. NF- B p65 and p50 
components are present at FcRn introns in vivo in response to TNF-α. THP-1 cells were 
treated with TNF-α (50 ng/ml) for 30 min. ChIP assays were performed using p65- (lanes 1-3 
and p50- (lanes 4-6) specific antibodies. IgG was used as a negative control (lanes 3 and 6). 








fold) in comparison with the other intronic NF-κB binding sequences (2.1 fold). 
Overall, the results support the notion that these NF-κB binding sequences are 
functional. 
 
Mutual interactions between promoter and intronic NF-κB of human FcRn gene 
            Considering that NF-κB-dependent induction of genes involves the cooperative 
interactions between NF-κB and other transcription factors (118, 119), we speculated 
that the intronic NF-κB binding sequences might also act upon the upstream FcRn 
promoters through a DNA looping mechanism. The chromosome conformation 
capture (3C) assay has proven to be an effective method to analyze the interactions 
between genomic regions, such as promoter-enhancer or enhancer-enhancer 
interactions, in gene regulation (112). We used the 3C assay to investigate the 
mechanism through which the distant NF-κB binding sequences regulate the FcRn 
gene. Intact nuclei isolated from live THP-1 cells were cross-linked with  
formaldehyde to fix segments of genomic DNA that are in close physical proximity 
(Fig 2.6 A). The cross-linked DNA was then digested with Hind III (Fig. 2.6 B) and 
ligated at a low concentration of DNA, and the ligated DNA was then analyzed by  
PCR using primers in all possible combinations (1F + 2R, 1F + 3R, 1F + 4R, 1F + 
5R) (Fig. 2.6 B). The appearance of a positive PCR product signals successful 
ligation and DNA looping. 
 
        As shown in Fig. 2.6 B, the primer H1F (Table II.I) which anneals to the 






















Figure 2.5 NF-κB binding sequences from FcRn introns can enhance the transcription of 
luciferase gene. A. A schematic representation of constructs pLuc-MCS containing NF-κB binding 
sequences from human FcRn introns 2 and 4. The pLuc-MCS plasmid has the minimal promoter with a 
TATA box. The plasmids, pLuc-MCS+1104, pLuc-MCS+5561, pLuc-MCS+9651, and pLuc-MCS+3463, 
were constructed as described in Materials and Methods. NF-κB sequences are underlined. Numbers 
represent the locations of NF-κB sites in the human FcRn gene. A DNA sequence corresponding +3463 
was used as a negative control. B. HT-29 monolayers were cotransfected with the pLuc-MCS reporter 
plasmids as indicated, and the NF-κB transactivator plasmid p50/65 in addition to Renilla luciferase pRL-
TK control plasmid. The pLuc-MCS backbone serves as a negative control. Luciferase activity was 




































As shown in Fig. 6B, the primer H1F (Table 2) which anneals to the promoter region 
sequence of the FcRn gene was used as an anchor primer to pair with other test 
primers (Table 2) in the Hind III-digested and ligated fragments. In Fig. 6C, PCR 
reactions from three primer pairs (1F+1R, 1F+2R, 1F+5R) yielded positive products 
(Fig. 6C, lanes 4 and 5). The PCR product from the primer pair 1F+2R and 1F+5R  
 
             
 
 
Figure 2.6 Chromosome conformation capture (3C) analysis of interaction between 
promoter and downstream human FcRn gene. A. Schematic representation of the 3C 
technology in analyzing human FcRn gene regulation.PC, protein complexes. B. Locations of Hind 
III sites and PCR primers in the 15-kb FcRn gene are shown. Positions of the six Hind III restriction 
sites (perpendicular bars) from the transcriptional start site of the FcRn gene are indicated. C. The 
3C assay. THP-1 cells were mock-treated (lanes 2 and 4) or stimulated by TNF-α (50 ng/ml) for 20 
minutes (lanes 3 and 5). Chromatin material was cross-linked and digested with excessive amounts 
of Hind III, ligated, and amplified by PCR.  Primer 1F was the anchor primer, and the others 
amplified from 5' to 3'. In lane 1, random ligation control templates were generated by amplifying 
the genomic DNA fragment with primers that amplify across the Hind III sites. Equimolar amounts 
of five different PCR products were mixed and digested with Hind III overnight at 37 °C. Ligated 
DNA was used to generate control PC  ts by using a combinat on of primer pairs listed in 
Table II.I to monitor the efficiency of ligation. Hind III-digested chromosomal DNA were used as 
template for PCR to examine the efficiency of Hind III digestion (Lanes 2 and 3). Ligated templates 
after dilution were used to PCR amplify after Hind III digestion and ligation (Lanes 4 and 5). Input 
DNA was used as an internal control for PCR reaction.  D. Sequence analysis of PCR products from 
3C analysis. PCR products were sequenced to confirm the fidelity of Hind III digestion and ligation. 
The Hind III sites were underlined in ligated products.  
 






other test primers (Table II.I) in the Hind III-digested and ligated fragments. In Fig. 
8C, PCR reactions from three primer pairs (1F+1R, 1F+2R, 1F+5R) yielded positive 
products (Fig. 2.6 C, lanes 4 and 5). The PCR product from the primer pair 1F+2R 
and 1F+5R was sequenced to confirm the fidelity of ligations and PCR amplifications 
(Fig. 2.6 D). The primer 1F+1R produced positive products from the ligated DNA 
template in both stimulated and unstimulated cells (Fig. 2.6 C, lanes 4 and 5).  To 
exclude the possibility that the observed PCR products were a result of random 
collisions as the result of the inherent flexibility of chromatin (112, 113) and of 
independent of the Hind III digestion, we also analyzed unligated samples after Hind 
III treatment for overnight (Fig. 2.6 C, lanes 2+3). We failed to detect corresponding 
bands amplified by PCR from the non-ligated DNA template. To monitor the 
differences in PCR amplification and ligation efficiencies, an additional control was 
used by mixing all restriction fragments from Hind III-digested PCR fragments 
(1F+1R, 2F+2R, 3F+3R, 4F+4R, 5F+5R) in equimolar amounts. After ligation at a 
high DNA concentration, all possible ligation products were present in the sample 
and amplified by PCR (Fig. 2.6 C, lanes 1). Taken together, we conclude that there 




            Activation or inhibition of NF-κB signaling pathway can regulate human FcRn 
expression. Proinflammatory cytokines TNF-α as well as TLR ligands, are well 







Table II.I   3C primers used in this study 
   H1F  5’-GAACTCGGATAGAGGTGACAGTTGCAC-3’ 
   H1R  5’-CCGAGATTGCACCACTGCACTCCAGAC-3’ 
  H2F  5’-CGCAGCAGTACCTGAGCTACAATAGC-3’ 
   H2R  5’-GAGGTGTTGTCAGGGCCCAGTTCACAG-3’ 
   H3F  5’-AGGAAGCGAGCATCCCATCACTGAGAC-3’ 
    H3R  5’-GCAGTGAGCCGAGACTGAGCCACTACAC-3’ 
    H4F  5’-GCTTTGGTAAATCTCAGACATCACAGTG-3’ 
  H4R  5’-GTCAGGAGTTCAAGACCAGCCTGGCC-3’ 
  H5F  5’-GCCCTTTGCATCCTGTGATGTTGCTG-3’ 






















TNF-α, CpG, and LPS augmented the FcRn expression in THP-1 and HT-29 cell 
lines, or freshly-isolated human monocytes in both mRNA and protein level (Figs 
2.1&2.2). This result is in concordance with studies that TNF-α induces MHC class I 
and polymeric IgA receptor (114, 120) expression. Interestingly, we observed that the 
activation dynamics of FcRn expression exhibited an oscillatory behavior when cells 
were stimulated by TNF-α but lengthened period when stimulated by LPS treatment. 
This observation is in agreement with the NF-κB expression patterns induced by 
TNF-α and LPS (121). Furthermore, we observed that FcRn expression induced by 
TNF-α was strongly counteracted by the NF-κB specific inhibitor CAPE. This was 
corroborated by the fact that over-expression of the dominant-negative 
IκBα (S32Α/S36Α) almost completely abrogated FcRn transcriptional activation 
induced by TNF-α (Fig 2.3 B). This complementary experiment lessens concern of 
specificity or toxicity of the chemical inhibitor. Interestingly, over-expression of 
either NF-κB did not affect FcRn basal expression in the absence of TNF-α 
stimulation.  It is possible that TNF-α treatment may modify the chromatin structure, 
allowing NF-κΒ, or NF-κΒ+ΙκBα, to become more accessible to their binding sites. 
It has been shown that TNF-α stimulation can remodel chromatin by histone 
acetylation (118, 122). More importantly, TNF-α also induces the binding of NF-κB 
to κB-like sequences in the promoter of human β2m gene (123). Therefore, activation 
of NF-κB by TNF-α, and possibly other NF-κB activators, could coordinately up-
regulate the expression of both FcRn and β2m genes. This balanced regulation of 




significance, since the noncovalent association of FcRn heavy chain and β2m is 
critical for FcRn to exit the endoplasmic reticulum (111).  
 
           NF-κB binding sequences were identified in the intronic regions of human 
FcRn gene. It was unclear whether NF-κB regulates FcRn expression directly or 
through an indirect mechanism by inducing other transcription factors which, in turn, 
could bind to the FcRn gene. Our data showed FcRn mRNA exhibited the rapid 
kinetics, usually within 20–30 min, in response to stimuli in our experiments. Our 
inhibition experiment by cyclohexmide further showed that the induction of FcRn 
mRNA was mediated without newly-synthesized protein factors. In fact, three NF-κB 
binding sequences were mapped in our ChIP experiment to the second and fourth 
introns of the human FcRn gene (Fig. 2.4). This is in concert with the observed TNF-
α-induced expression of other genes through intronic NF-κB-dependent mechanisms 
(111, 119, 120, 123). Notably, a large number of studies identify NF-κB binding 
sequences within noncoding introns (124, 125). The data presented here extend this 
concept and support an inducer-specific role for intronic regulatory elements in the 
transcription of human FcRn. Several interesting aspects should be perceived. First, 
the NF-κB binding sequences identified in the introns of human FcRn were not 
completely conserved, based on the NF-κB consensus binding sequence (Fig. 2.4 B). 
However, the apparent binding sequence for NF-κB is very broad and displays a 
certain degree of degeneration (126). Second, multiple NF-κB isoforms can be 
detected in nuclear extracts of activated cells. These isoforms may compensate for 




       
             NF-κB per se is clearly involved in the transcriptional regulation of many 
genes. Its activity can be modulated significantly by factors that bind to motifs 
adjacent to, overlapping with or distant from that of NF-κB binding sequences (110). 
In this regard, Sp1 elements may be strong candidates because they are often found in 
the enhancers or promoters of NF-κB-regulated genes (118, 127, 128). Additional 
studies have suggested that NF-κB dimers can act synergistically with NF-IL-6, AP-1, 
and Ets transcriptional factors to influence gene regulation (129, 130). Most 
importantly, the 5'-proximal promoter region of human and rodent FcRn shares 
numerous putative consensus sequences that are recognized by Sp1, AP-1, Ets, and 
NF-IL6 (131, 132). These protein-protein interactions may be involved in mediating 
the transcriptional regulation of FcRn gene in response to stimuli and can functionally 
cooperate to elicit maximal activation of the promoter. Further studies are needed to 
determine whether and how NF-κB and other transcriptional factors in the introns and 
promoter cooperatively regulate FcRn expression. 
 
          What might be the biological significance of regulation of FcRn by NF-κB 
signaling via intronic binding sequences? NF-κB is activated by exposure of cells to 
many physiological and non-physiological stimuli. Thus, regulation of FcRn 
expression in vivo likely involves the coordinated action of numerous modulatory 
factors. Tight control of FcRn may be especially important because FcRn plays a 
critical role in maintaining IgG homeostasis. This function results in the maintenance 




extends the life span of pathogenic or autoimmune IgG, potentially promoting the 
progression of autoimmune diseases. Humans with lupus have been shown to have 
elevated TNF serum levels (133), which could exacerbate their condition based on 
these findings. Therefore, the level of FcRn expression may be directly coupled to the 
pathogenesis and treatment of autoimmune diseases. NF-κB-based regulation of FcRn 
expression may have certain advantages. Since the promoter of IκBα gene contains 
NF-κB binding sites, NF-κB is able to autoregulate the transcription of its own 
inhibitor. As a result, the NF-κB activation of gene expression is transient in nature. 
Therefore, this autoregulatory control of NF-κB and IκBα expression may, in turn, 
maintain FcRn expression and be the basis of IgG homeostasis. Additionally, FcRn 
transports normal or neutralizing IgG across polarized epithelial cells potentially 
‘seeding’ neonatal and mucosal immunity. FcRn expression elevated from the basal 
level by cytokines or TLR ligands, or during mucosal infections, could facilitate a 
local immune response and/or promote the transport of IgG to mucosal surfaces and, 
thereby, allow rapid eradication of infectious agents. This result is further supported 
by the fact that the activated macrophages are a major source of TNF-α in intestinal 
inflammation. By examining the molecular mechanisms by which NF-κB regulates 
FcRn expression using human cell lines or freshly-isolated cells, our studies may 
contribute toward the general understanding of FcRn-mediated mucosal immunity and 
IgG-mediated autoimmune diseases. The in vitro results described in the present 
study are likely paralleled by in vivo events when NF-κB activation causes enhanced 






            In summary, the unusually-long intron of the FcRn gene contains sequences 
that bound either p65/p50 heterodimers or p50/p50 homodimers of the NF-κB 
transcription factors. The presence of NF-κB binding sequences located in distant 
intronic regions suggests NF-κB complexes may play an important role in the 
regulated expression of FcRn, possibly in cooperation with other transcriptional 
elements in the FcRn promoter. Because the FcRn protein may exert both beneficial 
and detrimental effects in a variety of infectious and autoimmune diseases, FcRn 
biosynthesis may be under the control of multiple complex regulatory mechanisms in 
response to an extracellular stimulus. Understanding the complex regulation of this 



















CHAPTER 3:  TRANSCRIPTIONAL REPRESSION OF FcRn BY 




             
            Expression of many MHC genes is enhanced at the transcriptional or 
posttranscriptional level following exposure to the cytokine IFN-γ. However, we here 
found that IFN-γ down-regulated the constitutive expression of the neonatal Fc receptor 
(FcRn), a MHC class I-related molecule that functions to transport IgG across polarized 
epithelial cells and protect IgG and albumin from degradation. Epithelial cell exposure to 
IFN-γ resulted in significant decrease of human FcRn expression, as assessed by real-
time RT-PCR and Western blot. The down-regulation of FcRn was not caused by 
apoptosis or the instability of FcRn mRNA. Chromatin immunoprecipitation and gel 
mobility shift assays showed that STAT-1 bound to an IFN-γ activation site (GAS) in the 
human FcRn promoter region. Luciferase expression from an FcRn promoter-luciferase 
reporter gene construct was not altered in JAK1- and STAT-1-deficient cells following 
exposure to IFN-γ. Furthermore, the repressive effect of IFN-γ on the FcRn promoter was 
selectively reversed or blocked by mutations of the core nucleotides in the GAS 
sequence. Functionally, IFN-γ stimulation dampened bidirectional transport of IgG across 
a polarized Calu-3 lung epithelial monolayer. Taken together, our results indicate that 
JAK-STAT-1 signaling pathway was necessary and sufficient to mediate the down-






      IFNs are multifunctional cytokines that have antiviral, antiproliferative, antitumor, 
and immunomodulatory effects (90, 134). In the case of IFN-γ, the cell membrane 
receptor for IFN-γ  is composed of two subunits, IFN-γR1 and IFN-γR2. Upon 
binding to IFN-γ, the IFN-γ receptor rapidly associates with the Janus tyrosine 
kinases JAK1 and JAK2. JAK enzymes phosphorylate one another and then 
subsequently phosphorylate the IFN-γ receptor, which results in the formation of a 
docking site for the latent cytoplasmic transcription factor named STAT-1, a member 
of the STAT (signal transducer and activator of transcription) protein family (92). 
Upon phosphorylation, STAT-1 homodimerizes, translocates to the nucleus, and 
regulates gene transcription by binding to IFN-γ-activated sequences (GAS) in the 
IFN-γ-inducible genes. Homodimerization of STAT-1 is mediated by the binding of 
the phosphorylated tyrosine 701 of one STAT-1 monomer to the Src homology 2 
domain of another. However, maximal transcriptional activity by active STAT-1 
homodimers also requires STAT-1 phosphorylation at serine 727 (135, 136). It has 
been found that STAT-1 phosphorylation plays a critical role in IFN-mediated innate 
immunity to microbial infection (137). STAT-1 signaling can also be negatively 
regulated by the protein inhibitor of activated STAT-1 (PIAS1) and suppressor of 
cytokine signaling (SOCS) (96). IFN-γ can also regulate expression of its inducible 
genes in a STAT-1-independent manner (138, 139), suggesting that multiple signaling 




            The pivotal roles in the protection and transport of IgG have led to an 
increasing interest in the mechanism that regulates FcRn expression regarding both 
constitutive and stimulated expression. MHC class I and related molecules include 
HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, HLA-H, MR1, MIC A/B, CD1, and FcRn. 
Expression of several MHC class I genes significantly increases at the transcriptional 
or posttranscriptional level following exposure to IFN-γ in a variety of tissues and 
cells (140-145). Although the transactivating roles of IFN-γ in MHC class I and its 
related molecules are well established, at present little is known about whether and 
how IFN-γ regulates FcRn gene expression. In an effort to identify the role of IFN 
signaling in regulation of the FcRn receptor, we unexpectedly found, for the first time, 
that IFN-γ down-regulated human FcRn expression and function. Furthermore, our 
study showed that activation of STAT-1 is required for IFN-γ-induced down-
regulation of FcRn expression. STAT-1-repressed FcRn transcription may act through 
sequestering the transcriptional coactivator CREB binding protein (CBP)/p300, thus 
reducing the level of CBP/p300 at the human FcRn promoter.  
 
MATERIALS AND METHODS 
Cell lines, Abs, reagents  
         Human lung-derived Calu-3 adenocarcinoma cells were obtained from American Type 
Culture Collection (HTB-55) and maintained in a 1:1 mixture of DMEM and Ham’s F-12 
medium (Invitrogen). Human 2fTGH cells, a cell line derived from the human fibrosarcoma 
HT1080 cell line, and the 2fTGH-derived cell lines U3A (STAT-1 deficient) and U4A (JAK1 




E2A4 (JAK1 deficient) was from Dr. R. A. Flavell (Yale University School of Medicine, 
New Haven, CT). The human intestinal epithelial cell lines HT-29 and Caco-2 and the 
macrophage-like THP-1 cells were obtained from Dr. R. S. Blumberg (Harvard Medical 
School, Boston, MA). The human intestinal epithelial cell line T84 was from Dr. W. Song 
(University of Maryland, College Park, MD). All epithelial and fibrosarcoma cells were 
maintained in DMEM complete medium (Invitrogen). All complete medium was 
supplemented with 10 mM HEPES, 10% FCS, 2 mM L-glutamine, nonessential amino acids, 
and penicillin (0.1 µg/ml)/streptomycin (0.292 µg/ml) in a humidified atmosphere of 5% CO2 
at 37°C.  
            
            HRP-conjugated donkey anti-rabbit or rabbit anti-mouse Ab was purchased from 
Pierce, and purified human IgG was from Jackson ImmunoResearch Laboratories. Anti-
STAT-1 , anti-phospho-STAT-1 (tyrosine 701), anti-phospho-STAT-1 (serine 727), and anti-
p300 Abs were from Cell Signaling Technology. Human recombinant IFN-γ was from R&D 
Systems. All DNA-modifying enzymes were purchased from New England Biolab.  
 
Semiquantitative RT-PCR and quantitative real-time RT-PCR  
           Semiquantitative RT-PCR and real-time RT-PCR were performed as previously 
described (146). In brief, total RNA was isolated from stimulated and mock-stimulated cells 
(2 x 106/ml) in TRIzol reagents (Invitrogen) according to the manufacturer’s instructions. 
Semiquantitative RT-PCR was performed using a one-step RT-PCR kit (Qiagen). Primers for 
amplification of FcRn and GAPDH have been previously described (146). Thirty cycles of 




at 94°C for 30 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s. An additional 10 
min was applied for the final extension. PCR products were resolved on 1.5% agarose gels 
and visualized by staining with ethidium bromide. Integrated density values for the FcRn 
binds were normalized to the GAPDH values to yield a semiquantitative assessment.  
           
           The freshly isolated human PBMCs (106 cells/ml) were stimulated with IFN-γ (25 
ng/ml) for 24 h. The total RNA samples were extracted. The RNA (400 ng/reaction) was 
reverse transcribed to yield first-strand cDNA using SuperScript III (Invitrogen). Real-time 
RT-PCR was performed using FcRn and GAPDH primers (146) and the SYBR Green 
Supermix kit (Bio-Rad Laboratories) in a Chromo 4 thermocycler (MJ Research). FcRn 
expression was calculated following normalization to GAPDH levels by the comparative 
threshold cycle method. All reactions were performed for 40 cycles: 15 s at 94 °C, 15 s at 58 
°C, and 20 s at 72 °C. The specificity of the amplification reactions was confirmed by melt 
curve analysis. The Opticon Monitor 3.1 software package (Bio-Rad Laboratories) was used 
for real time RT-PCR.  
 
Construction of expression or reporter plasmids and mutagenesis  
         Construction of the human FcRn promoter-luciferase reporter plasmid phFcRnLuc 
containing sequences from –1801 to +863 of the human FcRn promoter has been previously 
described (146). The mutant derivative plasmids pM1 and pM2 were constructed by 
overlapping PCR mutagenesis to disable the putative GAS sequence (see Fig. 3.3 B), using 





AGGATTAGTGGACGTTCAGCTGGTTCAGAG-3') or pM2 (5'-
TTATATGATTCAATGGCTTAGACATGTGCAGAATAG-3' and 5'-
TATGAAGTCTTTCCTTCCTTCCTTCCTTGCCTC) were used (the mutations are 
underlined). The expression plasmid encoding wild-type STAT-1 (pSTAT-1) and the 
phosphorylation site mutant plasmid pSTAT-1Y701F were kindly provided by Dr. K. 
Nakajima (Osaka City University Medical School, Osaka, Japan) and Dr. D. Geller 
(University of Pittsburgh, Pittsburgh, PA). The FLAG-tagged STAT-1 and PIAS1 expression 
plasmids were kind gifts from Dr. K. Shuai (University of California, Los Angeles, CA). The 
FLAG-tagged pSTAT-1Y701F, pSTAT-1S727A, or pSTAT-1Y701F/S727A was constructed 
by the overlapping PCR mutagenesis method. The primer pair (5'-
AGGAACTGGATTTATCAAGACTGAGTTGAT-3' and 5'-
TTAGGGCCATCAAGTTCCATTGGCTCTGGT-3') was used to substitute tyrosine 701 
with a phenylalanine residue (underlined). The primer pair (5'-
GACAACCTGCTCCCCATGGCTCCTGAGGAG-3' and 5'-TGTGGTCTGAAGTCTA 
GAAGGGTGAACTTC-3') was used to change serine 727 to alanine (underlined). The 
murine JAK1 expression construct was obtained from Dr. J. Ihle (St Jude Children’s 
Research Hospital, Memphis, TN). The integrity of the DNA fragments in the plasmids was 
confirmed by DNA sequence analysis.  
 
Immunoprecipitation, gel electrophoresis, and Western blotting  
          Immunoprecipitation was done as described previously (111). Protein was precipitated 
with anti-FLAG Ab. The immunoreactive products were eluted from the protein G complex 




previously described (108) (111). Protein concentrations were determined by the Bradford 
method. The cell lysates were resolved by electrophoresis on a 12% SDS-polyacrylamide gel 
under reducing conditions. Proteins were electrotransferred onto a nitrocellulose membrane 
(Schleicher & Schuell). The membranes were blocked with 5% nonfat milk, probed 
separately with affinity-purified rabbit anti-FcRn peptide (CLEWKEPPSMRLKARP) Ab for 
1 h, followed by incubation with HRP-conjugated donkey anti-rabbit Ab. All blocking, 
incubation, and washing were performed in PBST solution (PBS and 0.05% Tween 20). 
Proteins were visualized by an ECL method (Pierce).  
 
Determination of mature FcRn mRNA stability  
         Stability of the mature FcRn mRNA transcript was determined by using an actinomycin 
D inhibition assay as described previously(147, 148). Briefly, after 24 h of HT-29 cells being 
treated with or without IFN-γ, 5 µg/ml actinomycin D (Sigma-Aldrich) was subsequently 
added to each culture to stop the further production of mature FcRn transcript. Following the 
addition of actinomycin D, cell viability was analyzed by trypan blue exclusion and did not 
significantly change over the course of the experiment. HT-29 cells were collected from the 
cultures at 0, 1, 2, 4, 8, and 10 h following the addition of actinomycin D, and total RNA was 
isolated. The level of FcRn mRNA was quantified for each time point by semiquantitative 
RT-PCR or quantitative real-time PCR as described above.  
 
Nuclear run-on assay  
           The rate of mature FcRn transcription was determined by nuclear run-on as described 




stimulation in the presence or absence of IFN-γ and washed twice with PBS before 
resuspension in 5 ml of cell lysis buffer containing 10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 
3 mM MgCl2, and 0.5% Nonidet P-40 for 5 min at 4°C. Nuclei were collected by 
centrifugation at 300 x g for 10 min at 4°C, resuspended in 500 µl of nuclear freezing buffer 
containing 50 mM Tris-HCl (pH 8.3), 40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA, and 
stored at –80°C until use for nuclear run-on. Nuclear run-on and RNA isolation were 
preformed in the presence of biotin-16-UTP (Roche). To control for the possibility of 
nonbiotin-labeled RNA contamination, replicate sets of nuclei were used in the nuclear run-
on that did not contain biotin-16-UTP. Dynabeads M-280 (Invitrogen) were used to capture 
the biotin-labeled RNA molecules from the purified nuclear RNA, and beads were washed 
twice with 2x SSC plus 15% formamide and once with 2x SSC and resuspended in 30 µl of 
RNase-free H2O before the preparation of random hexamer-primed cDNA as described in the 
paragraph titled Semiquantitative RT-PCR and quantitative real-time RT-PCR above except 
for the primer pair used for GAPDH (5'-GCCACTAGGCGCTCACTGTTCTCTC-3' and 5'-
CTCCTTGCGGGGAACAGCTACCCTGC-3') and FcRn (5'-
GAGCCTGGGCGCAGGTGAGGGCCGC-3' and 5'-
GCGACAGGTGGTTCCCAGCCTCAGGC-3'). Primers located in the intronic region are 
underlined. All samples that did not contain biotin-16-UTP were found to be negative for the 
presence of GAPDH and mature FcRn transcripts.  
 
Immunofluorescence and detection of apoptosis by TUNEL  
          HT-29 cells were cultivated on coverslips for 24 h. The coverslips were rinsed in PBS 




procedures were done at room temperature. After two washings with PBS, the coverslips 
were permeabilized (3% BSA and 0.2% Triton in PBS) for 30 min. Cells were incubated with 
affinity-purified rabbit anti-STAT-1 in PBST (0.05% Tween 20 and PBS) with 3% BSA for 1 
h. Cells were then incubated with Alexa 458 Fluor-conjugated AffiniPure goat anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories) in PBST with 3% BSA. Cell nuclei were 
counterstained with 5 µg/ml 4',6'-diamidino-2-phenylindole (DAPI; Molecular Probes) in 
PBS. After each step the cells were washed three times with 0.1% Tween 20 in PBS. To 
mount coverslips, the ProLong antifade kit was used (Molecular Probes). Images were 
captured using a x100 oil-immersion objective on a Zeiss inverted microscope linked to a 
DeltaVision deconvolution imaging system.  
            
            In situ detection of apoptotic cells was performed with the TUNEL kit from Roche. 
After IFN-γ (50 ng/ml) treatment, HT-29 cells undergoing cell death were identified. Briefly, 
IFN-γ- or mock-treated cells were fixed with a freshly prepared fixation solution (4% 
paraformaldehyde in PBS (pH 7.4)) for 1 h at room temperature, and then incubated in 
permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) for 2 min on ice, and 
the TUNEL procedure was conducted according to the manufacturer’s instructions. For the 
correlation of TUNEL with nuclear morphology, cells were counterstained with DAPI. To 
confirm the specificity of TUNEL, cells were treated with 3000 U/ml DNase I at room 
temperature for 10 min to induce DNA strand breaks before labeling procedures. In negative 
controls, terminal TdT was omitted from the labeling reaction mixture. Samples were viewed 





Transient transfection and luciferase assay  
           Transient transfection and luciferase assay were done as previously described (146). 
Briefly, cells were transiently transfected with Effectene according to instructions from the 
manufacturer (Qiagen). In each cotransfection, 2 x 106 cells were transfected with a DNA mix 
containing 0.95 µg of firefly luciferase reporter plasmid and 0.05 µg of Renilla luciferase 
pRL-TK control plasmid. The following day, the cells were cultured with or without IFN-γ. 
The cells were harvested 24 h after treatment and assayed for the expression of Renilla and 
firefly luciferase using the dual luciferase kit (Promega) according to the recommended 
protocol in a Victor 3 luminometer (PerkinElmer). The values for firefly luciferase were 
normalized to the Renilla luciferase activity and expressed as fold activation over the vector 
background.  
 
Chromatin immunoprecipitation (ChIP)  
          ChIP experiments were performed according to the manufacturer’s recommendations 
(Upstate Biotechnology) and as previously described(146). In brief, HT-29 cells (5 x 106 
cells) were incubated with or without IFN-γ (25 ng/ml) for 1–12 h. The cells were fixed with 
1% formaldehyde. The nuclei were isolated and sonicated 20 times on ice for 10–20 s with 
90-s breaks (Sonifier 350; Branson) between each sonication interval to shear the DNA to 
200-1000 bp. A small aliquot (20 µl) was saved as "input DNA" for PCR analysis by 
reversing histone-DNA crosslinks by heating at 65°C for 4 h. Chromatin was 
immunoprecipitated from 200-µl aliquots at 4°C by mild agitation overnight with 5 µg of Ab 
specific for STAT-1, phospho-STAT-1 (tyrosine 701), and phospho-STAT-1 (serine 727) or 




incubation with protein A-agarose. To analyze the target region, the immunoprecipitated 
chromatin DNA samples were amplified by PCR with primer pairs for FcRn (5'-
GGAAAGACTTCATATTATATGATTC-3' and 5'-
GCAACTGTCACCTCTATCCGAGTTC) or ICAM-1 (5'-
GATTGCTTTAGCTTGGAAATTC-3' and 5'-GGAGCCATAGCGAGGCTGAG-3'). DNA 
samples or input DNA fractions were analyzed by 35 cycles of PCR (94°C for 30 s, 58°C for 
30 s, and 72°C for 30 s) in 20-µl reaction mixtures. PCR products were subjected to 
electrophoresis by using 2% agarose gels in TAE (Tris-acetate-EDTA) buffer and visualized 
by ethidium bromide.  
 
Preparation of nuclear extracts and EMSA  
            Nuclear extracts were prepared using a nuclear and cytoplasmic extraction kit 
according to the manufacturer’s instructions (Pierce). IFN-γ (25 ng/ml)-treated HT-29 cells (1 
x 107) were used. The double-stranded oligonucleotides (5'-
TGATTCAATTTCTTTGAAATGTGCAG-3') containing a putative GAS sequence 
(underlined) from the FcRn promoter was used. The double-stranded oligonucleotides (5'-
CCCTTTCTGGGAAGTCCGGGT-3') containing the GAS sequence (underlined) from the c-
myc promoter were used as a positive control. The DNA was labeled with a biotin 3'-end 
DNA labeling kit (Pierce). In brief, 4 µg of nuclear extracts were incubated in binding buffer 
(10 mM Tris (pH 7.9), 50 mM NaCl, 5 mM MgCl2, 50 mM KCl, and 50% glycerol) with 50 
ng/ml poly(deoxyinosinic-deoxycytidylic acid) (poly(dI-dC)) and a 20-fmol final 
concentration of biotin-labeled, double-stranded oligonucleotide for 20 min at room 




nonlabeled oligonucleotide. For the supershift assay, 0.8 µg of each Ab specifically directed 
against STAT-1 was preincubated with the nuclear extracts in the absence of poly(dI-dC) for 
30 min at 22°C. Subsequently, poly(dI-dC) was added and incubated for 5 min, followed by 
the addition of a probe for an additional 20 min. The samples were loaded on a 5% native 
polyacrylamide gel in 0.5x Tris-borate-EDTA buffer at 80 volts for 2 h. The gels were blotted 
onto a nylon membrane (Bio-Rad Laboratories), blocked, incubated with HRP-avidin, and 
developed using the LightShift chemiluminescent EMSA kit (Pierce) according to the 
manufacturer’s instruction. Visualization of the chemiluminescent signal on the membrane 
was achieved by exposing to X-ray film (Kodak).  
 
IgG transcytosis  
         IgG transport was performed with a modification of previously described methods (149, 
150). Calu-3 cells were grown onto Transwell filter inserts (Corning Costar) to form a 
monolayer exhibiting transepithelial electrical resistances (700 ohms/cm2). Transepithelial 
electrical resistance was measured using a tissue-resistance measurement equipped with 
planar electrodes (World Precision Instruments). Monolayers were equilibrated in HBSS and 
mock-treated or stimulated with IFN-γ (25 ng/ml) for 24 h. Thereafter, human IgG at a final 
concentration of 0.5 mg/ml was added to the apical or basolateral medium. Monolayers were 
incubated for 1 h with IgG or chicken IgY at 37°C. An aliquot of the buffer was collected into 
which apically and basolaterally directed IgG or IgY transport was conducted. Transported 
proteins were analyzed by reducing SDS-PAGE and Western blot-ECL. NIH Image software 
(National Institutes of Health, Bethesda, MD) was used to determine the relative band 




Statistical analysis  
          Data from three independent experiments were initially analyzed by ANOVA to detect 
significant changes between the stimulated and mock-stimulated cells. Additional statistical 
evaluation of the differences in expression of FcRn genes was measured by Student’s t test 
with a Bonferroni correction. All results are expressed as mean values. A value of p < 0.05 
was considered significant.  
 
RESULTS 
Exposure of cells with IFN-γ down-regulates the expression of FcRn  
        IFN-  has been shown to enhance the expression of the MHC genes at the 
transcriptional or posttranscriptional level (140, 141). To determine whether IFN-γ regulates 
human FcRn gene expression, we treated human intestinal epithelial cell lines that express 
FcRn (61, 149) with IFN-γ (50 ng/ml). Our data showed that FcRn gene expression in T84 
and HT-29 cells was down-regulated in response to IFN-γ treatment as shown by 
semiquantitative RT-PCR (Fig. 3.1A). To rule out whether this decrease in FcRn was the 
result of general transcriptional decreases in the cell, we also measured the transcript for the 
MHC class II-associated invariant (Ii) chain, a molecule highly up-regulated by IFN-γ. 
Transcript levels for Ii (Fig. 3.1A, bottom panel) were significantly increased by IFN-γ, 
suggesting that the transcriptional down-regulation of FcRn is specific. The decreased 
expression of FcRn protein in HT-29 cells was shown by Western blotting in IFN-γ-
stimulated cells (Fig. 3.1B, top panel, lanes 2–4) in comparison with mock-stimulated cells 
(lane 1). Lysates from HeLa-FcRn and HeLa were used as a positive (Fig. 3.1B, lane 3) and 




protein synthesis, we performed additional experiments where the levels of FcRn mRNA 
were determined following treatment with cycloheximide (CHX), an established inhibitor of 
protein synthesis. In these experiments we used a concentration of CHX (25 µg/ml) at which 
>95% of protein synthesis is blocked within 1 h (151). The results showed that the IFN-γ-
induced transcriptional repression was totally independent of new protein synthesis. 
Specifically, by RT-PCR analysis we observed 60% reduction in FcRn mRNA synthesis 
following 24 h of exposure to IFN-γ in the presence of CHX, an overall inhibition 
comparable with that obtained in the absence of CHX (Fig. 3.1C). these data indicated that 
preexisting proteins were modified in a ligand-dependent manner to repress the FcRn gene.  
 
Effect of IFN-γ on FcRn mRNA stability, rate of mRNA transcription, and 
apoptosis  
          The primary mechanisms that regulate the amount of mRNA produced in 
mammalian cells are transcript stability and/or the rate of mRNA transcription. As 
such, we ascertained whether either of these mechanisms was involved in regulating 
the decrease in mature FcRn mRNA in the absence or presence of IFN-γ. Using an 
actinomycin D inhibition assay as shown by semiquantitative RT-PCR (Fig. 3.2 A, 
left panel) and quantitative real-time PCR (Fig. 3.2 A, right panel), the half-lives of 
FcRn mRNA appeared to be similar between mock- and IFN-γ-treated cells for the 
indicated time period. This suggests that a stability mechanism was not likely 
responsible for the decrease in FcRn mRNA. In contrast, nuclear run-on analysis 
indicated that the rate of FcRn mRNA transcription was decreased 80% in THP-1 


















Figure 3.1 Down-regulation of human FcRn expression in epithelial cells by IFN- . 
*, p < 0.05. A. Down-regulation of human FcRn and up-regulation of Ii occur concomitantly in 
response to IFN-  treatment. Human intestinal cell lines were treated with (+) IFN-  (lanes 3, 5, 
and 7) or without (–) IFN-  (lanes 2, 4, and 6) (50 ng/ml) for 48 h. GAPDH amplification was 
used as an internal control. B.Western blot analysis of FcRn expression. The cell lysates (20 µg) 
from mock-treated (lane 1) and IFN- -stimulated HT-29 (lane 2) Cell lysates from HeLa-FcRn 
(lane 3) and HeLa (lane 4) were used as positive or negative controls, respectively. The ratio of 
the mock group is assigned a value of 1.0, and the values from other groups are normalized to 
this value. The ratios of FcRn and β-tubulin are shown as indicated. C. Effects of CHX on IFN-
-mediated repression of FcRn expression. Human intestinal HT-29 cells were incubated with (+) 
or without (–) the protein synthesis inhibitor CHX (25 µg/ml) for 2 h as indicated. HT-29 cells 
were subsequently stimulated with (+) or without (–) IFN-  (25 ng/ml) for 24 h. At the end of 





FcRn mRNA induced by IFN-γ-stimulation on a HT-29 or THP-1 cell is due to a 
decrease in the rate of primary FcRn RNA transcription. 
           
           In addition, activation of the STAT-1 signaling pathway can cause expression 
of caspase 1 and subsequent apoptosis (152). To further assess the possible role of 
IFN-γ in inducing apoptosis in our experiment, HT-29 cells were pretreated with or 
without IFN-γ (50 ng/ml) for the indicated time periods (Fig. 3.2 C). A TUNEL assay 
demonstrated that IFN-γ induced detectable apoptosis in a small fraction of HT-29 
cells only following 120 h of incubation (Fig. 3.2 C). Mock-treated HT-29 cells were 
stained TUNEL negative at 120 h; cells stained after treatment with DNase I were 
used as a positive control (Fig. 3.2 C, panel labeled "PC"), and cells without IFN-γ 
treatment or those stained without TdT were used as a negative control (Fig. 3.2 C, 
panel labeled "NC"). Collectively, neither instability of FcRn mRNA nor significant 
apoptosis was induced by IFN-γ when used for this period of time (24–48 h) and at 
these concentrations (50 ng/ml) in our experiments. 
Identification of STAT-1 binding site in the FcRn promoter  
        IFN-stimulated response elements (ISRE) and IFN-γ activation site (GAS) 
motifs are present in a variety of IFN-inducible genes (90, 134). ISRE (consensus 
sequence AGTTTCNNTTTCNY) and GAS (consensus sequence TTNCNNNAA, 
TTCNNNG/TAA) binding motifs have been mapped (90, 134, 153). We searched for 
putative ISRE and GAS sequences along the entire human FcRn promoter (GenBank 
accession no. AC010619). Computational inspection revealed that the FcRn gene 





























Figure 3.2. Kinetic studies of FcRn mRNA levels and apoptosis in the absence or 
presence of IFN- . A. Human intestinal HT-29 cells were preincubated for 24 h in the absence or 
presence of IFN-  (25 ng/ml). Actinomycin D (5 µg/ml) was then added; total cellular RNA was 
harvested at the indicated time points (1–10 h). Ten nanograms of total RNA were reverse 
transcribed to cDNA in a final volume of 20 µl. Subsequently, 30 cycles of semiquantitative RT-
PCR (A, left panel) or a real-time RT-PCR (A, right panel) were performed. Electrophoresis of 10 
µl of PCR product was done on 1.5% agarose gel (left panel). FcRn values were normalized for 
GAPDH with each sample. FcRn product at time 0 before the addition of actinomycin D was plotted 
as 100%. B, Nuclear run-on analysis was performed on THP-1 nuclei isolated in the presence of 
biotin-16-UTP for 30 min. Biotinylated RNA was collected using streptavidin magnetic beads, and 
the level of FcRn or GAPDH RNA was determined by quantitative real-time RT-PCR. Data are 
mean ± SD of three independent experiments. C. TUNEL staining of human intestinal epithelial HT-
29 cells. After mock treatment or IFN-  (50 ng/ml) treatment at the indicated times, in situ detection 
of apoptotic cells was performed on HT-29 cells cultured on coverslips by using an in situ cell death 
detection kit. Treatment with DNase I as a positive control (PC) or stained without terminal 
deoxynucleotide transferase as a negative control (NC). For the correlation of TUNEL with nuclear 
morphology, cultures were counterstained with DAPI (5 µg/ml). Red represents apoptosis positive 








however, it had two sequences with a similarity to the STAT-1 consensus target 
sequence (Fig. 3.3 A). To quickly screen whether these two sequences arefunctional 
in the transcriptional repression of FcRn by IFN-γ, we set up a transient cell 
transfection assay using the FcRn promoter/luciferase reporter gene construct 
phFcRnLuc (146). We also generated constructs pM1 and pM2, each of which 
contains mutations of the putative GAS sequence in phFcRnLuc (Fig. 3.3 A). 
Transient transfection revealed that the phFcRnLuc or pM1 construct had decreased 
expression of luciferase in response to IFN-γ stimulation in wild-type 2fTGH cells 
(Fig. 3.3 B). However, transient transfection of the pM2 construct revealed that 
mutation of this putative GAS sequence significantly increased the luciferase activity 
in IFN-γ-stimulated cells to a similar level as that in mock-stimulated cells (Fig. 3.3 
B). Hence, we conclude that the GAS sequence (TTCTTTGAA) in the human FcRn 
promoter is functional in response to IFN-γ stimulation (Table  III. I ).  
           
           To verify that this putative GAS sequence has the capability to directly bind 
STAT-1 protein in living cells, a ChIP assay was used to precipitate the STAT-1-
DNA complexes with an Ab specific for STAT-1. After cross-linking the DNA with 
bound STAT-1 proteins in situ in IFN-γ-stimulated vs mock-stimulated HT-29 cells, 
the DNA fragments containing the STAT-1 sequences in FcRn promoter were 
precipitated with Ab and measured by PCR amplification. As shown in Fig.3.3 C, 
PCR with primers flanking the putative STAT-1 sequences generated a band from 
DNA coprecipitated with STAT-1 (lanes 2 and 3). In a negative control, 






         











products (Fig. 3.3 C lane 4). The STAT-1 binding sequence in the ICAM-1 gene 
promoter (154) was used as a positive control. As expected, ChIP assays failed to 
detect DNA bands from U3A cells (Fig. 3.3 C, lanes 5 and 6).  
         
          To further visualize the capability of STAT-1 protein to directly bind to the 
putative FcRn GAS site identified from the ChIP assay, EMSAs were conducted to 
confirm the ChIP assay by using oligonucleotides containing the putative GAS 
sequence. As shown in Fig. 3.3 D, oligonucleotides formed a complex with extracts 
from IFN-γ-stimulated cells (lane 2) but not from mock-stimulated cells (lane 1). An 
oligonucleotide containing the GAS sequence from the c-myc promoter was used as a 
positive control (Fig. 3.3 D, lane 9). To verify whether the binding was specific, a 
competition assay was performed. The inducible band could be completely competed 
away by unlabeled oligonucleotides (lane 3). Supershift analysis revealed that the 
complex contains a factor that was recognized by Ab specific for the STAT-1 protein 
(lane 4) but not normal IgG (lane 5). 
 
IFN-γ induces the in vivo association of p300 and STAT-1α, and overexpression of 
p300 reduces IFN-γ -mediated FcRn gene repression  
          Our data show that the nuclear translocation of STAT-1α correlated with IFN-γ 
-mediated down-regulation of FcRn gene transcription and that STAT-1α bound 
directly to the FcRn promoter (Fig. 3.3). It is possible that nuclear protein(s) 






















































































Figure 3.3  Identification of IFN-  responsive element in human FcRn promoter. 
A.The putative STAT-1 binding sequences in FcRn gene promoter. STAT-1 binding sequences 
from ICAM1 and c-myc as a positive control. The consensus STAT-1 sequence is in boldface. N 
represents any nucleotide. Reporter construct phFcRnLuc contains the FcRn promoter sequence 
from –1801 to +863 kb. The putative GAS mutations (underlined bases) in constructs pM1 and 
pM2 are also shown. Arrowheads indicate the position of the STAT-1 binding site in relation to 
the transcription start site of the FcRn gene. Luc, Luciferase. B. Identification of GAS sequence in 
response to IFN-  stimulation. Wild-type 2fTGH cells were transiently transfected with 
phFcRnLuc, pM1, and pM2 constructs. Twenty-four hours after transfection, cells were either 
mock-treated (filled bar) or treated with IFN-γ (open bar) for 24 h. Cells were then harvested and 
protein extracts were prepared for the luciferase assay. C. Detection of the in vivo binding of 
STAT-1 protein to the human FcRn promoter in a ChIP assay. ChIP assays were performed using 
STAT-1-specific Abs (lanes 1–3, 5, and 6) or isotype-matched IgG (lane 4) as a negative control. 
D.EMSA analysis of binding activities of DNA probe with nuclear extracts from HT-29 cells 
treated with (+) or without (–) IFN- . A 26-bp fragment spanning the putative STAT-1 binding 
sequence corresponding to the GAS was used as a biotin-labeled probe. Binding specificity of 
these complexes was examined by competition assays with a 100-fold molar excess of unlabeled 
STAT-1-specific probe (lane 3). Supershift experiments were performed in the presence of the 





expression. It is known that STAT-1α can bind CBP/p300 (147). Therefore, we 
further examined the possibility that the interaction between STAT-1α and CBP/p300 
may lead to down-regulation of FcRn gene expression. Coimmunoprecipitation was 
used to examine the in vivo association of endogenous p300 and STAT-1α. The 
2fTGH and U3A cells were incubated in the absence and presence of IFN-γ and 
nuclear extracts from these cells were subjected to immunoprecipitation with Ab 
against p300. The precipitated immune complexes were then blotted for the presence 
of STAT-1α. In IFN-γ-treated cells, anti-p300 Ab immunoprecipitated a significant 
amount of STAT-1α (Fig. 3.4 A lane 2) in comparison with mock-stimulated cells 
(lane 1). As a negative control, IgG did not immunoprecipitate STAT-1α (lane 3). 
These results suggest that STAT-1α does not associate with p300 in mock-stimulated 
cells; however, IFN-γ treatment can induce the in vivo association of STAT-1α and 
p300.  
         
         It is possible that STAT-1α suppresses FcRn gene activation by interfering with 
the binding of CBP/p300 to the FcRn promoter. Transient transfection assays were 
first used to examine whether overexpression of p300 could reverse IFN-γ-mediated 
FcRn suppression. Indeed, overexpression of p300 reversed IFN-γ-induced 
suppression of luciferase expression in a dose-dependent manner (Fig. 3.4 B). 
Therefore, these data suggest that the IFN-γ-induced interaction between STAT-1α 













































Figure 3.4  IFN-  induces the in vivo association of p300 and STAT-1 , and 
overexpression of p300 blocks IFN- -mediated FcRn gene down-regulation. A. The 
2fTGH (lanes 1–3) and U3A (lane 4) cells were treated with IFN-  (10 ng/ml) or mock treated 
for 2 h and then nuclear extracts were obtained and subjected to immunoprecipitation. Anti-p300 
mAb (lanes 1, 2, and 4) and isotype-matched IgG (lane 3) were used to immunoprecipitate the 
STAT-1  and p300 complex. B. HT-29 cells were transiently transfected with increasing 
amounts (0.1–0.4 µg) of a p300 construct, and the total amount of transfected DNA was 
normalized by pcDNA3. Transfected cells were treated with IFN-  or mock treated for 14 h. 





IFN-γ reduced bidirectional transport of IgG in polarized lung epithelial 
monolayers  
          The FcRn protein has been shown to transport IgG bidirectionally in polarized 
epithelial cells, namely from the apical to the basolateral direction or vice versa (148). 
We therefore addressed the possibility that IFN-γ-stimulated epithelial cells have 
altered IgG transcytosis. Calu-3 cells have been previously shown to transcytose 
dimeric IgA in response to IFN-γ stimulation (155). We established the FcRnin Calu-
3 cell lines and further verified the FcRn down-regulation by IFN-γ stimulation, as 
assessed by semiquantitative RT-PCR (Fig. 3.5 A).  
            
           In our transport experiment, after adding human IgG to the apical or 
basolateral surface of a Calu-3 cell monolayer, we assessed the IgG transported to the 
opposite basolateral or apical chamber following IFN-γ exposure, respectively. As 
expected, after 1 h at 37°C intact human IgG applied to the apical or basolateral side 
was transported across this monolayer. IgG H chain was detected in medium 
incubated at 37°C (Fig. 3.5 B, upper row). Importantly, IgG transport was decreased 
30% in the apical to basolateral direction (Fig. 3.5 B, lane 3), or 40% in the 
basolateral to apical direction (Fig. 3.5 B, lane 5) following IFN-γ stimulation, in 
comparison to the mock-treated monolayer (Fig. 8C, lanes 2 and 4). Treatment of 
Calu-3 monolayers with IFN-γ for 24 h might result in a leakage of IgG molecules, as 
shown in human intestinal epithelial cell line T84. Chicken IgY was used as a 
negative control because it is structurally similar to human IgG but does not bind to 

























Figure 3.5  Effects of IFN-  stimulation on the IgG transcytosis.  
A. Semiquantitative RT-PCR analysis of FcRn mRNA in the human lung epithelial Calu-3 
cell line. The Calu-3 cells were treated (+) with IFN-  (25 ng/ml) (right lane) or left untreated 
(–) (left lane) for 24 h. B.Calu-3 cells (5 x 105/well) were grown in a 12-well Transwell plate. 
When the resistance of the monolayer reached 700-1000 ohms/cm2, cells were stimulated with 
or without IFN-  (25 ng/ml) for 24 h. Cells were loaded with human IgG (top row) or chicken 
IgY (bottom row) (0.5 mg/ml) at 4°C in either the apical (lanes 2 and 3) or basolateral (lanes 4 
and 5) chamber. Lane 1 represents an IgG or IgY H chain. Cells were warmed to 37°C to 
stimulate transcytosis, and medium was collected from the nonloading compartment 1 h later 
and subjected to Western blot-ECL analysis. The results are representative of at least three 
independent experiments. Band intensities of IgG heavy chain (HC) were compared by 




















in either direction, suggesting that the transepithelial flux of Abs by passive diffusion 
through intercellular tight junctions or monolayer leaks does not contribute to the 
amount of the IgG we detect. Therefore, we concluded that IFN-γ stimulation 
decreased the IgG transport across the polarized epithelial cells.  
 
DISCUSSION 
             Transcriptional regulation of genes hinges on the ordered recruitment of 
transcriptional polymerase, coactivators, repressors, chromatin modifiers/remodelers, 
and general transcriptional factors to the promoters of target genes. How the gene 
transcriptional machinery integrates signals from different biological signaling 
pathways is a central question for gene regulation. Exposure to IFN-γ can result in the 
regulation of up to 500 genes in either a positive or a negative way (134, 138). Genes 
that are negatively regulated by IFN-γ are fewer in number than those positively 
induced. Among the negatively regulated ones are some of the MMPs, stromelysin, 
type II collagen, HL-60, neu/HER-2, cell-cycle genes (c-myc, cyclin D, cyclin A), 
granulocyte chemotactic protein-2, IL-4, prolactin, perlecan, and the scavenger 
receptor A (SR-A) genes (138, 156-164). In this article we report, for the first time, 
the effect of IFN-γ on the transcriptional regulation of FcRn.  
          
         Activation of the IFN-γ signaling pathway down-regulates the expression of the 
human FcRn gene, and this down-regulation is dependent on the STAT-1 signaling 
pathway. This conclusion is supported by several pieces of evidence. First, our results 




epithelial cells, Second, a nuclear run-on assay demonstrated that this down-
regulation indeed occurred at transcription initiation (Fig. 3.2 B). Third, we have 
mapped an IFN-γ-responsive sequence, GAS, to the promoter region of the human 
FcRn gene by both EMSA and ChIP. Mutation of this GAS sequence abolished the 
inhibitory effect of IFN-γ on FcRn promoter (Fig. 3.3). Fourth, expression of 
luciferase activity driven by the FcRn promoter following IFN-γ exposure was not 
affected in STAT-1-null U3A in comparison with the wild-type cell 2fTGH. These 
results provided both biochemical and genetic support for the conclusion that 
increased phosphorylation of STAT-1 is the mechanism by which IFN-γ treatment 
leads to FcRn down-regulation. Recent studies have shown that IFN-γ can regulate 
gene expression by STAT-1-independent pathways(138). Among several genes that 
are inhibited by IFN-γ, c-myc has been shown to require STAT-1-dependent and 
STAT-1-independent pathways and, notably, there is a GAS element in the c-myc 
promoter that is necessary, but not sufficient, to confer the total inhibitory effects of 
IFN-γ. Therefore, our data support the conclusion that the down-regulation of human 
FcRn expression was mediated via a STAT-1-dependent pathway in response to IFN-
γ. However, our data could not exclude the possibility that STAT-1 may bind to sites 
in other parts, such as introns, of the human FcRn gene. We considered the possibility 
that IFN-γ induces apoptosis(152) and regulates the expression of the gene at 
posttranscriptional level. However, several facts counter this conjecture. First, down-
regulation of human FcRn and up-regulation of Ii occurred concomitantly in response 
to IFN-γ treatment (Fig. 1A). Second, we failed to detect any noticeable effect of IFN-




the half-life of FcRn mRNA was not affected by IFN-γ. Third, apoptosis was only 
detected after a 5-day period and then only in a few cells (Fig. 3.2 D). In addition, the 
level of IFN-γ repression (40–50%) on the reporter construct phFcRnLuc was similar 
to FcRn gene repression in cell lines; this would exclude the possibilities that the 
down-regulation of FcRn gene expression might be caused by apoptotic effects of 
IFN-γ or that IFN-γ affects the half-life and stability of FcRn mRNA. Therefore, these 
complementary experiments eliminate the concerns of apoptotic effects or stability of 
FcRn mRNA by IFN-γ.  
          
         The mechanism of STAT-1-mediated down-regulation of human FcRn 
expression might be through sequestering of the transcription activator CBP/p300. 
One potential mechanism by which IFN-γ might normally mediate the repression of 
FcRn transcription could be via STAT-1 interaction with either constitutive 
transcription factors or transcription factors that are activated upon exposure to IFN-γ. 
Although STAT-1 acts as an activator of transcription in numerous genes in response 
to IFN-γ stimulation, the detailed mechanisms by which STAT-1 switches on and off 
gene expression are still unclear. As shown in several elegant studies, although STAT-
1 is necessary and sufficient to inhibit MMP-9, SR-A, and type II collagen gene 
transcription by IFN-γ, there are no GAS elements in the promoters of these genes 
(156, 165). Thus, suppression of the expression of these genes by IFN-γ -activated 
STAT-1 is probably not dependent on the direct binding of STAT-1 on the gene 
promoter of these genes. In contrast, the suppression of the MMP-9 or the SR-A gene 




Indeed, STAT-1 can interact with a variety of other transcription factors, including 
STAT-2, CBP, p300, p300/CBP cointegrator protein (pCIP), histone deacetylase 1 
(HDAC-1), N-Myc interactor (Nmi), and BRACA1 (166-169). Among these proteins, 
CBP/p300 serves as a scaffold in transcription complex formation in addition to 
functioning as histone acetyltransferases. Given the fact that the total amount of 
CBP/p300 is limited compared with the amount of other transcription regulators, a 
competition for using CBP/p300 in different signaling pathways has been proposed. In 
the case of the MMP-9, SR-A, neu/HER-2 genes, activated STAT-1 can 
competitively bind with CBP/p300, thereby resulting in decreased association of 
CBP/p300 in the gene promoter and interference with the assembly of functional 
transcription complexes (159, 165, 166). Our data showed that overexpression of 
CBP/p300 overcame the inhibitory effect of IFN-γ (Fig. 3.4 B). However, our data 
could not exclude the possibility of STAT-1 interacting with other transcription 
factors. For example, Y-box-binding protein YB-1, RFX5 complex, CIITA, IFN 
regulatory factor (IRF)-1, and IRF-2 are also involved in the gene repressions by IFN-
γ (135, 161, 169, 170). Further work is underway to determine how STAT-1 actually 
mediates repression of FcRn gene expression.  
           
         To date, two biological functions have been attributed for FcRn: transcytosis of 
IgG across polarized epithelial cells and protection of IgG from degradation. The level 
of FcRn expression may be critical for the regulation of IgG levels in tissues and 
blood. First, mucosal Abs are important for mucosal infections, and epithelial cells 




pathogen-specific neutralizing IgG across polarized cells such as placental or mucosal 
epithelial cells, potentially "seeding" maternal and mucosal immunity. From our 
findings, one might speculate whether IFN-γ dampening the expression of the FcRn 
receptor might lead to the lessening of IgG transport. In an in vitro Transwell model, 
our results clearly demonstrated that IFN-γ functionally decreased IgG transport in the 
polarized lung epithelial Calu-3 cell line (Fig. 3.5 B). Therefore, IFN-γ may dampen 
IgG-mediated mucosal immunity by reducing IgG transport in vivo. This result is in 
contrast to the fact that IFN-γ up-regulates pIgR expression, which is expected to 
enhance secretory IgA-mediated mucosal immunity (155, 171). Furthermore, our 
previous finding revealed that TNF-α and IL-1β, via activation of the NF-κB 
signaling pathway, can up-regulate the functional expression of FcRn. Because IFN-γ, 
TNF-α, and IL-1β are proinflammatory cytokines, FcRn levels may therefore be 
finely tuned by opposing negative and positive signaling in the maintenance of IgG 
homeostasis under pathophysiological conditions. Thus, regulation of FcRn 
expression in vivo likely involves the species, magnitudes, and coordinated actions of 
proinflammatory cytokines or other functional regulators. Secondly, by mediating the 
protection of IgG from catabolism, FcRn extends the half-life of pathogenic or 
autoimmune IgG, potentially promoting the progression of IgG-mediated autoimmune 
diseases (106). Therefore, by influencing the expression level of FcRn, IFN-γ may be 
directly coupled to the pathogenesis of IgG-mediated autoimmune diseases. Indeed, 
IFN-γ has been shown to regulate the intensity or the progression of several 
autoimmune diseases (172). However, it remains for further investigation whether its 




through the down-regulation of FcRn expression. This question merits further 
investigation in a murine model. Overall, by examining the molecular mechanisms by 
which IFN-γ regulates FcRn expression, our studies may contribute toward the 
general understanding of FcRn-mediated mucosal immunity and inflammation. The 
identification and understanding of IFN-regulated FcRn gene expression may lead to 
improved therapies for IgG-mediated autoimmune diseases.  
           
           Among MHC class I-related molecules, IFN-γ causes the up-regulations of the 
MHC genes HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, HLA-H, HLA-E, and CD1 
(141). The promoters of HLA-A, HLA-B, HLA-C genes contain a consensus ISRE 
sequence. IRF-1 is induced by IFN-γ and interacts with the ISRE in HLA gene 
promoters to stimulate transcription initiation (141). In the special case of HLA-E, 
although IFN-γ also induces HLA-E expression, the HLA-E gene promoter does not 
contain a functional ISRE. Instead, two distinct elements in the HLA-E promoter are 
termed the IFN response region (IRR) and the upstream IFN response region (UIRR). 
STAT-1 and GATA-1 bind to the IRR and UIRR, respectively, to stimulate 
transcription from the HLA-E promoter (173). Among the MHC class I-related genes, 
FcRn is an only molecule that is down-regulated by IFN-γ (Fig. 3.6). This scenario 
makes FcRn unique in the response to IFN regulation. Therefore, understanding 
differences in the mechanisms by which IFN-γ stimulates MHC-I genes and FcRn 
could be of great interest in the settings of immune responses and autoimmunity. Any 












Figure 3.6. Schematic illustration of transcription factors binding to the promoter 
region of some MHC class I-related genes after IFN-γ treatment. The ISREs of HLA-A, 
HLA-B, HLA-C, and HLA-F bind IRF-1 upon IFN-γ exposure and regulate the IFN-γ-induced 
transactivation of these genes. The putative ISRE of HLA-E did not respond to IFN-γ-stimulation, 
whereas an upstream GAS sequence of HLA-E is responsive to IFN-γ through STAT-1 activation. 
HLA-G is responsive to IFN-γ via an upstream IFN-responsive regulatory sequence. Multiple 
putative ISREs of CD1D are predicted, but one is shown here. Human FcRn responds to IFN-γ 
through STAT-1 activation and binding to an upstream GAS sequence. In addition, several 
constitutive transcription factors are revealed to bind to the ISRE area. Sp1 binds to the GC-rich 
sequences in the ISRE areas of HLA-B, HLA-C, and HLA-G. The putative E box 5' of the ISRE in 
most HLA-BE alleles is bound by USF-1 and USF-2. Arrows represent the up- and down-
regulation of gene expression upon IFN-γ exposure. The schematic structure of the gene promoter 





the FcRn and MHC class I genes would be potential targets for therapeutic 










          
          In summary, transcriptional repression of FcRn gene expression by IFN-γ is 
dependent on activated STAT-1 protein. These findings suggest that the biological 
consequence of IFN-γ -induced transcription of the FcRn gene is distinct from that of
other MHC class I or related genes. Therefore, our observation that FcRn repression 
by IFN-γ is, to our knowledge, the first demonstration that MHC class I-related genes 
are regulated negatively by IFN-γ exposure. These results provide evidence that I
γ differentially modulates the expression of FcRn and MHC class I or its related 
genes, which generates opposing effects on cellular and humoral immunity. Further 
studies of STAT-1-mediated mechanism of transcriptional repression on FcRn will 
provide insights into understanding the inhibitory effects of IFN-γ on gene expression 
in general. Given the important role of FcRn in the maintenance of IgG concentrat







CHAPTER 4: FCRN MEDIATES EFFICIENT ANTIGEN PRESENTATION 
OF PHAGOSOMAL IMMUNE COMPLEXES IN MACROPHAGE, BUT NOT 






            While Fc gamma receptors (FcγRs) facilitate MФ and DC presenting IgG-
restricted Immune complexes (ICs) onto MHC class II molecules efficiently, the role 
of another IgG Fc receptor, neonatal Fc receptor (FcRn) remains elusive. We now 
show that the phagosomal FcRn in MФ binds to uptaken latex-ICs, prolongs the half 
life of latex-IC, and enhances the MHC-II-restricted antigen presentation. However, 
defective FcRn has no effects on the antigen processing and presentation of latex-ICs 
in DC both in vitro and in vivo. We show that phagosomes in MФ are acidified very 
rapidly, that is required for the physical interaction of FcRn with IC. By contrast, DC 
maintains the neutral environment of phagosomes for a long time, which prohibits 
FcRn from binding to IC, consequently unable to affect the antigen process and 
antigen presentation. Our studies reveal a novel mechanism for FcRn to modulate the 















            
            Uptaking, processing and presenting exogenous antigens to T lymphocytes by 
professional antigen-presenting cells (APC) such as MФ and DC is a crucial step to 
initiate the immune responses (99). MФ and DC express FcγRs on their surfaces. 
Functionally analogous to the B cells receptor for antigen presentation, FcγRs could 
internalize antigen in the form of immune complexes and facilitate MHC class II-
restricted antigen presentation and MHC class I-restricted cross-presentation (9, 174, 
175). FcγRs-internalized IC are transported through endocytic pathway, to late 
endosomes or phagosomes, where IC is fragmented and loaded onto MHC class II 
molecules for  presentation to T cells (175). Furthermore, the binding of IC to FcγRI 
and FcγRIII triggers the activation signaling through the γ subunit (FcRγ) that carries 
an immunoreceptor tyrosine-based activation motif (ITAM) (176). The signal through 
the FcγRs induces the maturation of DC and promotes antigen presentation (174). 
 
             The neonatal Fc receptor for IgG (FcRn) is structurally and functionally 
different from FcγRs. FcRn consists of one membrane-bound 45-50 kDa heavy chain 
and one 12 kDa light chain β2-microglobulin (β2m). The structure and sequence 
analysis show that FcRn shares homology with MHC class I molecule (26, 47). 
Despite of the structure similarity, the peptide groove of FcRn is occluded (28, 171). 
Instead, FcRn binds Fc portion of IgG on the outer face of the narrowed groove, 
which involves both heavy chain and β2m. Several histidines residing in CH2 and 
CH3 domains of IgG are key residues directly contact FcRn, which are distinct from 




to fetus or to the newborn across epithelial and endothelial barriers (36, 56). FcRn 
also can transport IgG and complexed antigens across intestine epithelium (177). This 
transcytosic function is accomplished by FcRn capturing IgG or ICs on the cell 
surface or in the endosomes, transporting them across the polarized cellular barriers. 
FcRn also acts as salvage receptors diverting the bound IgG away from lysosomal 
degradation and maintaining IgG homeostasis (67, 68, 178). These two functions of 
FcRn are dependent on the ability of FcRn to bind IgGs, which is pH restricted and 
only occurs at the pH ≤ 6.5 (27). 
 
            The pH value in the endocytic compartments of professional APCs plays a 
very important role to control the degradation of exogenous antigen following their 
uptake (179), as lysosomal degradation could destroy antigenic epitope for 
presentation. The high antigen presenting efficiency of DC is partially due to the pH 
regulation in different maturation stages and in different endocytic compartments. 
Particularly, the alkalinization of phagosomes provides DC the ability to control 
degradation for optimal presentation (101, 180). The rapid acidification of 
phagosomes in MФ results in a strong activation of lysosomal proteases and effective 
protein degradation (181, 182). Our recent studies show that in DC and MФ, FcRn 
localizes in late endosomes/lysosomes in addition to the early endosomes (183, 184). 
In this study, we compared the roles of FcRn in antigen processing and antigen 
presentation in DC and MФ. We showed that FcRn can facilitate antigen presentation 
by stabilizing the IgG-complexed antigens in a pH-dependent manner, which 





MATERAILS AND METHODS 
 
 Mice.  
           Seven-wk-old C57BL/6 mice were purchased from National Cancer Institute 
and Charles River Laboratories (Frederick, MD). Female B6.PL-Thy1a/CyJ (Thy1.1 
congenic) WT mice and OT-II mice (B6 background) transgenic for OVA323-339 were 
purchased from The Jackson Laboratory (Bar Harbor, ME). OT-I/RAG-/- (B6 
background) mice transgenic for OVA257-264 were kindly provided by ghost lab 
(NIAID, Bethesda, MD). MHC class II -/- mice on B6 background were purchased 
from Taconic (Rockville, MD). FcRn-/- B6 mice bearing Thy1.2 were used (68). 
Transgenic mice were bred and maintained in HEPA-filtered cages at the University 
of Maryland (College Park, MD). The studies detailed herein conform to the 




                   OVA (grade VI) was purchased from Sigma-Aldrich (St. Louis, MO). Rabbit IgG 
poly-Ab to OVA were purchase from MP Biochemicals (Solon, Oh). Rabbit IgG-
OVA immune complexes were made by mixing a 5:1 molar excess of anti-OVA: 
OVA at 37°C for 30min.  Mouse IgG mono-Ab to OVA was purchased from Sigma. 
Mouse IgG-OVA immune complexes were made by mixing 1:1 of anti-OVA: OVA 
at 37°C for 30min. Latex beads (3μm, fluorescent or nonfluorescent) were purchased 




OVA (10mg/ml) by incubation at 4°C for 48 hours. After then, the conjugated beads 
were washed with PBS for three times and stored in PBS at 4°C. Latex-OVA-ICs 
were made by mixing Latex-OVA with Rabbit anti-OVA at the ratio of 1:1.  LPS 
from Escherichia coli type 0111.B4 was abtained from Sigma-Aldrich (St. Louis, 
MO). Rat mAb anti-LAMP-1 was from the Developmental Studies Hybridoma Bank 
(Iowa City, IA). mAb anti-EEA1, rat anti-mouse transferrin receptor were obtained 
from BD Biosciences. All secondary Abs were purchased from Invitrogen. 
 
 Bone marrow-derived DCs (BMDCs).  
                     BMDCs were produced as described by Lutz et al (185) with minor 
modifications. In brief, bone marrow was flushed from the femurs of mice, and cells 
were plated in 100-mm petri dishes at a concentration of 1 x 106 cells/ml in RPMI 
1640 supplemented with 10% FCS, penicillin/streptomycin, HEPES, glutamine, 50 
µM 2-ME, and 10% GM-CSF-secreting J588L (kind gift from Dr. Kristin Tarbell, 
NIDDK) cell culture supernatant. On days 3 and 6, half of the medium was removed 
and replaced with fresh conditioned medium. On day 8, the suspension cells were 
             harvested and analyzed by found flow cytometry. Cells contained > 80% CD11c+/ I-
A/E positive cells. 
 
Splenic DC (SPDC).  
                     Spleen was digested by Collagenase D (Roache, IN) for 30 min at 37°C. Then, 
cells were passed through a strainer and washed with RPMI 1640. To separate DC,  




            following manufacture’s instruction. 
 
 Bone marrow-derived macrophages (BMMs).  
                     BMMs were prepared as described previously (186). bone marrow were 
obtained using a similar approach to that for BMDCs. Cells were plated in petri 
dishes in F12/DMEM Glutamax supplemented with 10% FCS, 
penicillin/streptomycin, glutamine, and 20% conditioned medium from the 
supernatant of M-CSF-secreting L929 fibroblasts. Media was replaced on day 3 and 
day6, and attached cells were used at 7-9 days for experiments. 
 
Antigen Presentation Assays.  
                     For MHC Class II–restricted antigen presentation assays. OVA, OVA-IC, and 
Latex-OVA-IC  was separately added to Immature DCs or MФ cells (1 x 105/well) in 
96-well microtiter plates were incubated with antigen in the presence of  LPS 200 
ng/ml for 12 h. Cells were then washed with PBS before adding OT-II CD4+ T cells 
at a concentration of 2 x 105/well. CD4+ T cells were purified from OT-II TCR 
transgenic mice by negative selection using CD4+ cell isolation kit (Miltenyi Biotec, 
CA). T cell responses were monitored at 24 h by measuring IL-2 accumulation in the 
supernatant by ELISA (BD Biosciences, CA). Data are from triplicate cultures.  
 
        For MHC Class I–restricted antigen presentation assays. Presentation of OVA 
epitope 257-264 on Kb was detected using the T cell hybridoma B3Z or OT-I T cells. 




promoter(187). OT-I CD8+ T cells were purified from OT-I/RAG-/- transgenic mice 
by negative selection using CD8+ T cell isolation kit (Miltenyi Biotec, CA). For 
antigen presentation assays, DC or MФ were exposed to OVA-IC, at the 
concentration and for the periods of time specified, in the presence of the T cell 
hybridoma B3Z or OT-I CD8+ T cells. After incubation, B3Z cells were lysated, and 
a colorimetric assay using ONPG (sigma) as a substrate was used to detect LacZ 
activity in B3Z lysates. IL-2 production in supernatant was measured by ELISA kit 
following incubation with OT-I T cells.  
 
Phagosomal pH measurement by confocol microscopy  
                    Phagosomal pH was measured as previous description (188, 189). Briefly, 
BMMs or BMDCs (2x105cells/well) were plated in 4-well coverglass bottom 
chamber (Lab-Tek, Nunc, IL). After 80 % cells attached to the chambers, 1x106 
Latex-Beads coated with Dextran-Lysosensor Yellow/Blue (Invitrogen, CA) were 
added to each well and incubated with cells for indicated times, and then the cells 
were washed with warm PBS 5 min before the Confocal examination. The 
microscope (Zeiss LSM 510 Thornwood, NY) were used for the measurement at 
excitation laser 405 nm, and an emission filter at 450 nm and a longer emission 
between 505-530 nm. The ratios of 530/450 nm emission from phagocytosed beads 
were calculated by the software Zen 2007.  
 
         To obtain pH standard curve, cells were incubated with Lysosenor-coated 




treated cells were equilibrated for 10 min with 25 mM MES (4-
morpholineethanesulfonic acid) buffer containg 5 mM NaCl, 115 mM KCl, 1.2 mM 
MgSO4 (from pH 5.0 to pH 7.5) prior to image acquirement. 
 
Measurement of HRP-IC uptake and processing.  
                      Horse radish peroxidase (HRP)-IC were generated by mixing HRP and rabbit 
anti-HRP (Sigma-Aldrich, MO) a 5:1 molar excess of anti-HRP:HRP at 37°C  for 
30min. After pulsed with HRP-IC for 3h at 37°C, cells were extensively washed and 
chased at 37°C for the indicated time point. The remaining HRP activities were 
represented by 450nm absorbance with TMB reagents. 
 
Adoptive transfer with antigen-pulsed DC and MФ.  
                     Bone marrow derived DC or MФ 5 x 105cells/ml were treated for 12 h in the 
presence of 100 μg/ml OVA, 10 μg/ml OVA-IC, and 10 μg/ml Latex-OVA-IC/ml in 
vitro. Free antigens were then removed from the cell cultures by washing about three 
times in cold PBS, each time followed by centrifugation for 10 min at 350 x g at 4°C. 
OVA323-339 peptide pulsed cells as positive control, ICs-pulsed cells were resuspended 
in fresh medium at 1 x 106 cells/200 µl, and then injected either s.c. or i.v. into each 
mouse (190). 
 
Analysis of CD4+ T cell proliferation ex vivo.  
                      The T cell recall response was measured as previously described (191, 192). On 




depending on the experiment. Nonpeptide-pulsed APCs were used as a negative 
control. On 5 days (DC immunization) or 15 days (MФ immunization), CD4+ T cells 
were isolated from the spleen and lymph nodes of immunized  mice and labeled with 
1 µM CSFE (Invitrogen) for 10 min at 37°C. The cells were then washed once with 
HBSS without Mg2+ and Ca2+ (Fisher Scientific), supplemented with 5% FCS, 
followed by serum-free HBSS.  2 x 105/200ul CFSE-labeled CD4+ T cells were 
restimulated with spleenic DC bearing OVA peptide OVA323-339 in the 96-well 
plate.  T cell proliferation was monitered with CFSE and PE-conjugated anti-Vα2 
(BD Pharmingen) 3 days later by flow cytometry (193). 
  
Immunofluorescence  
                         Immunofluorescence patterns were visualized with confocal microscopy as 
described (184, 194)  Briefly, cells were cultivated on Lab-Tek chamber (Nalge Nunc 
NY) for 12 h. Cells were pulsed with 1μg/ml OVA-DQ ( Invitrogen)-ICs for 1h and 
then washed with PBS, cold fixed in 3.7% paraformaldehyde for 30 min at 4°C, and 
quenched with glycine for 10 min. After two washes with PBS, the cells were 
permeabilized in solution (PBS containing 0.2% Triton X-100) for 20 min and then 
blocked with PBS containing 10% normal goat serum. The mouse FcRn was detected 





FcRn colocalizes with immune complexes (ICs) in the phagosomes of murine 




           FcRn has been shown to locate in early endosome and lysosomes of DC and 
MФ (184). We cultured bone marrow-derived DCs with J588L supernant and bone 
marrow-derived macrophages with L929 supernatant. In 8-10 days, FcRn was found 
highly distributed in early endosomes marked by Transferin receptor (TFR) of both 
BMDC and BMM by confocal microscope (Fig. 4.1 A),  in agreement with the 
previous findings (72, 183, 184). When OVA-IC labeled in green florescence was 
loaded to BMDC and BMM, FcRn in red was found colocolized with OVA-IC (Fig. 
4.1 B). To test if FcRn localizes in phagosomes, we feed BMDCs and BMMs with 
green florescent latex beads conjugated with OVA-ICs. We found that FcRn 
colocalized with latex beads, suggesting that FcRn was distributed to the phagosomes 
during the phagocytosis in DC and MФ (Fig. 4.1C). This is in agreement with the 
observation that FcRn resides in the phagosomes of neutrophils (195). 
 
In BMDC, FcRn enhances the presentation of endocytosed OVA-IC (mono), but 
not phagocytosed Latex-OVA-IC antigen through MHC class II. 
To assess the role of FcRn in antigen presentation through MHC class II 
pathway, we compared IL-2 production from the OT-II CD4+ T cells activated either 
by wild-type BMDC or by FcRn-/- BMDC. OT-II CD4+ T cells isolated from OT-II 
transgenic mice can recognize OVA peptide 323-339 aa presented by the MHC class 
II molecules I-Ab (B6 background). When exposed to OVA, FcRn deficiency had no 
effect on the ability of  DC to activate OT-II T cells (Fig. 4.2 D). As we know, 
soluble OVA was enocytosed into the cells and processed in the late 












Figure 4.1  Localization of FcRn in endosomal compartments of murine bone marrow-
derived DC and macrophage. BMMs (top) were isolated from 10th day culture in the presence of 
10% J588L supernatant, and BMDCs (bottom) were isolated from 7th day culture with 20% L929 
supernatant. The cells were fixed, permeabilized, stained, and analyzed by confocal microscopy. FcRn 
were visualized (red) using rabbit anti-FcRn-CT and Alexa 533-conjugated secondary antibodies. TFR 
(CD71) was detected by monoclonal rat-anti CD71 and Alexa 488-conjugated secondary antibodies. A, 
FcRn overlayed with early endosome marker TFR (green). B, some of the FcRn protein was colocalized 
with OVA-IC (green) in both BMM and BMDC.C, before the fixation, cells were pulsed with OVA-IC 
coated fluorescent Latex beads (green) for 2h, and then followed by the same staining procedure. 
Yellow, condistribution of two colors. Bar, represent 10μM.










restricted OVA-IC was exposed to the DCs, IL-2 production decreased modestly from 
OT-II T cell primed by FcRn-/- DC (Fig. 4.2 E) in comparison with WT DCs. These 
monoclonal IgG-restricted immune complexes also went through endosomes and 
lysosomes for antigen processing and presentation (Fig. 4.2 B). However, when DCs 
were incubated with latex beads conjugated with OVA-ICs, there was no difference 
on IL-2 production between WT DCs and FcRn-/- DCs primed T cells (Fig. 4.2 F), 
and these latex beads induced phagocytosis (Fig. 4.2 C). Similar results were obtained 
using polyclonal IgG-restricted immune complexs. Therefore, the expression of FcRn 
in BMDC promotes the presentation of antigen in ICs captured and processed through 
endocytosis, not through phagocytosis. 
 
In BMM, FcRn enhances both endocytosed OVA-IC and phagocytosed Latex-  
OVA-IC to MHC class II. 
           To examine the roles of FcRn-mediated antigen presentation of MФ, an in 
vitro T cell proliferation assay was conducted on BMM. BMM derived from WT and 
FcRn-/- bone marrow were pulsed with indicated concentrations of OVA-IC 
overnight, washed to remove extra ICs, and incubated with OT-II cells for 20 h. As 
shown in Fig. 4.3 E, the FcRn-/- BMM failed to prime the OT-II T cells. Similarly, 
the latex-OVA-ICs-treated FcRn-/- BMM also induced less IL-2 production in 
comparison with that of WT BMM (Fig. 4.3 F). In the control experiment, OVA 
loaded BMM, either WT or FcRn defective, activated CD4+ T to a similar level  
(Fig. 4.3 D). The trafficking patterns of immune complexes in MФ and DC are 









































































































































































































































































































































































































































































































































































































































































































































































FcRn does not affect the cross-antigen presentation by MHC class I. 
           The IC internalization through FcγRs in DC promotes both MHC class II and 
MHC class I restricted-antigen presentation (174, 196). We further addressed whether 
the FcRn-deficiency affected antigen cross-presentation in BMDC and BMM. CD8+ 
T cell hybridoma (B3Z) (187) were used to study presentation of exogenous OVA-
ICs. This hybridoma recognizes the OVA 257-264 peptide presented by MHC class I 
(H-2Kb). When incubated with high concentration of OVA or low concentration of 
latex-OVA-ICs, WT and FcRn-/- BMDC efficiently activated B3Z cells (Fig. 4.4 A 
and C). WT and FcRn-/- BMDCs that were incubated with mAb-derived OVA-ICs, 
failed to activate of B3Z T cells (Fig. 4.4 B). 
 
As shown previously (197), MФ was able to present the exogenous OVA on 
MHC class I molecules and to initiate the CTL response. However, the ICs did not 
enhance this process (198). To determine whether FcRn affects the cross-antigen 
presentation in MФ, B3Z T cells were primed with BMM. There was no contribution 
of FcγRs to BMM on the OVA-ICs cross-presentation as previously discussed (198), 
and the absent expression of FcRn in MФ did not affect activation of B3Z (Fig. 4.4 D, 
E, and F). To confirm these results, all the assays on B3Z cells were repeated on OT-I  
T cells, the data were consistent with results from B3Z T cells. Therefore, we 













































































































































































































































































































































































































The phagosomal pH is different between BMM and BMDC; FcRn can stabilize the  
internalized ICs in the acidic compartments. 
          It was demonstrated that the phagosomal localizations of FcRn had distinctive 
effects on antigen presentations between DC and MФ. We reasoned that the 
discrepancy might be related to phagosomal pH in DC and MФ, based on the feature 
of FcRn binding to IgG at acidic pH. 
        
          To measure the phagosomal pH value in both MФ and DC, we selected the pH 
sensor, soluble dextran-linked LysoSensor Blue/Yellow. This probe exhibits pH-
dependent dual-emission spectra. At acidic condition, the probe emits at the 
wavelength of 530 nm maximally, whereas at neutral pH, the emission fluorescence 
at 450 nm is stronger (188). Thus, the pH value is equally translated to the ratio of 
fluorescence at 530 (Green) to 450 (Blue). After exposing the LysoSensor (1mg/ml) 
coupled latex-beads to BMM or BMDC for 5 hours, phagosomal pH values were 
measured. We found that the Green/Blue ratio obtained from phagosomes in BMM 
was 1.7 (Fig. 4.5 C). In contrast, phagosomes in BMDC displayed a Green/Blue ratio 
of 1.1 (Fig. 4.5 B). Using a pH standard curve (Fig. 4.5 A), we concluded that the 
phagosomal pH in MФ was below 5.0, whereas phagosomal pH in DC was over 7.0. 
 
         We next asked how FcRn in BMDCs and BMMs regulated the presentation of 
IgG-restricted antigens. Because the antigen digestion rate correlates with the 
magnitude of antigen presentation, it is highly possible that FcRn protects uptaken 





















Blue  450nm                          Green  530nm                               Merge 
Figure 4.5  BMDC bears a phagosomal alkalinization, while phagosomes in BMM is 
acidic. BMDC (B), BMMs (C). A. Standard calibration curve for LysoSensor Blue/Yellow pH 
indicator. Day 9-BMDCs were incubated for 5h with Lysosensor Blue/Yellow (1mg/ml)-coupled 
latex beads (3μm) at 37°C, and equilibrated with MES buffers ( pH value from 5.0 to 7.5) containing 
nigericin and monensin. Emissions at 450 nm and 530 nm from phagosomal beads were measured 
with confocal microscopy at exitation 405nm. The ratio of 530/450 nm fluorescence (Green/Blue) is 
measured as described in Materials and Methods.  B. BMDCs were incubated with Lysosensor-
coupled latex beads for 5h at 37°C, Emission at 450 nm was shown blue ( Left ); emission at 530 nm 
was displayed green ( Middle); and the merged photo is on the right. The ratio of Green/Blue was 
calculated and shown on the right C. BMMs were exposed with Lysosensor-coupled latex beads for 




promotes the efficient epitopes loading onto the MHC class II molecules. To monitor 
the fates of internalized antigens in forms of ICs, Latex-beads-ICs or antigen alone in 
DC.  We treated WT or FcRn-/- BMDCs with HRP, HRP-ICs and HRP-Beads-ICs 
separately for 3h, washed cells, and then chased HRP activities at indicated time 
points. After extensive washes with PBS (pH 5.0), the cells were lysated and applied 
for spectrophotometer measurement in TMB substrate at wavelength of 450 nm. The 
remaining activities of HRP were measured and recorded (Fig. 4.6). When BMDC 
was loaded with HRP-IC, the remaining activities of HRP (red line) from WT BMDC 
(Fig. 4.6 A) decreased slower than that from FcRn -/- BMDC (Fig. 4.6 B). When 
BMDC were loaded with HRP-beads-ICs or soluble HRP, the degradation rates (Blue 
line or Black line) in WT BMDC were similar to that in FcRn-/- BMDC (Fig. 4.6 A, 
B). In contrast, the degradation rates of HRP-ICs and HRP-Beads-ICs in WT BMM 
were much slower than that of FcRn-/- BMM (Fig. 4.6 C, D). Therefore, it is 
concluded that FcRn could stabablize the immune complex in acidic phagosomes in 
MФ. 
 
FcRn enhances the ICs antigen presentation ex vivo. 
                    To further evaluate the contribution of FcRn mediated-antigen presentation in 
BMDC and BMM through MHC class II molecules ex vivo, we used an adoptive 
transfer system (175, 199). WT or FcRn-/- BMDC loaded with OVA, OVA-ICs or 
Latex-OVA-ICs were transferred to WT C57BL/6 mice. After 4 days, the draining 
lymph node (popliteal) was removed from these mice, and the CD4+ T cells were 







                    
            
A. 
Figure 4.6 The dynamic degradation of HRP, HRP-IC, and HRP-Beads-IC in both 
macrophage and DC.  WT BMDC (A.) and FcRn -/-BMDC (B.) was pulsed with HRP(▲), 
HRP-IC(■), and HRP-beads-IC(●) for  3 hours separately. After extensive washing, cells were 
incubated with fresh medium at 37°C for additional 3h, 6h, 9h, and 21h.   The reaminning HRP 
activites were measured by exposing the cell lysis to TMB reagent, and subject to the cytometric 
quantification at 450nm. The readout of 3h-pulsed samples were assigned as 100%, and the values 
of chase samples were calculated in comparison with pulse samples. Following the same procedure, 







            OVA323-339. The T cells from animals immunized with IC-loaded WT BMDC 
proliferated better than in the mice immunized with ICs-loaded FcRn-/- BMDC (Fig. 
4.7 A, second panel from right). In contrast, WT or FcRn-/- BMDCs loaded with 
Latex-OVA-ICs stimulated the CFSE-T cell proliferation to the similar extent (Fig. 
4.8 A, right panel). These results are consistent with in vitro data. In addition, T cells 
stimulated by OVA-loaded BMDCs proliferated equally (Fig. 4.7 A, second panel 
from left) 
 
       To further assess whether the presence of FcRn in BMM affects the T cells 
activation ex vivo, WT or FcRn-/- BMM was pulsed with ICs or Latex-OVA-ICs for 
4h, and then s.c.injected these loaded BMM to the C57BL/6 mice. CD4+ T cells 
isolated from the draining lymph nodes were labeled with CFSE and restimulated 
with OVA323-339 peptide. The results showed that FcRn in BMMs loaded with ICs 
or Latex-OVA-ICs enhanced the T cell proliferation (Fig. 4.7 B), in spite of the 
instensity of T cell proliferation was less than that of BMDC stimulation. 
Collectively, these data show that the binding of FcRn with IgG-restricted antigens in 
acidic pH is critical to allow DCs and MФ to present antigen and to activate naïve T 




          This study establishes a novel mechanism of the enhanced antigen presentation 














Figure 4.7  FcRn defective BMDC  impairs the antigen presentation of  
endocytosed ICs to CD4+ T cell ex vivo, whereas FcRn defective BMM impair 
both endosomal and phagosomal antigen to CD4+ T cell . A. Day-9 BMDC (WT, 
top panel or FcRn KO bottom panel) was pulsed separately with OVA (second left 
panel), OVA-IC (second right), and Latex-OVA-IC (right panel) for 12 h at at 37°C, 
and then the antigen-loaded cells were washed with PBS for three times. Pretreated cells 
were injected s.c into syngenic C57BL/6. As control, non-antigen treated BMDC were 
injected. After four day, CD4+ T cells were isolated from different immunization and 
labeled with CFSE, the secondary anti-OVA proliferative responses were measured by 
repriming of CFSE-CD4+T cells with spleen DC bearing OVA specific peptide323-336. B. 
Day-7 BMM were treated with three forms of antigen and injected into C57BL/6 mice 
described as above. Two weeks later, CFSE-labelled CD4+ T cells proliferation were gated 
and measured. 




antigen uptake and regulating maturation of APC cells. Our finding indicates that 
FcRn in endocytic compartments of DC and MФ protects the ICs from rapid 
catabolism in lysosomes and leads to increasing efficiency of antigen processing and 
peptide loading onto the MHC class II molecules. These data extend upon the unique 
ability of FcRn binding to IgG by now demonstrating a new function of FcRn in DC 
and MФ for antigen presentation, besides IgG protection and IgG transcytosis (57). 
We further demonstrated that FcRn in different endocytic compartments of DCs 
functioned differently during antigen presentation of IgG-ICs. It enhances antigen 
presentation of endocytosed ICs, but not phagocytosed ICs in DC. More interestingly, 
FcRn in MФ boosts antigen presentation of ICs uptaken through both endocytosis and 
phagocytosis. Furthermore, this discrapancy is shown due to the different pH among 
endocytic organelles. 
 
          Phagosomes in DC and MФ are considered as fully competent organelles for 
MHC class II and MHC class I antigen processing (175, 199). Efficient antigen 
processing in phagosomes requires the limited and controlled proteolysis of protein 
antigen. One of the most direct ways to control the activities of lysosomal proteases is 
the pH value adjustment. It has been shown in DC, that the recruitment of NADPH 
oxidase NOX2 to phagosomes mediates a sustained production of ROS, which 
consumes the proton in phagosomal lumen, causing the pH elevation to 7.4, even 
higher than the extracellular pH (180). This high pH in phagosomes provides DC with 
default control on proteases to digest the antigens properly. However, in MФ, due to 




very rapidly. This low pH facilitates FcRn binding with ICs and protect antigen from 
rapid degradation in MФ. Regarding the endosomes/lysosomes, the pH in both MФ 
and DC is acidic, which facilitates FcRn involving in the presentation of immume 
complexes antigen internalized through endosomes/lysosomes. 
 
           Although a variety of studies document the involvement of FcγRs in the 
receptor-mediated endocytosis (9), the mechanism of ICs internalization (endocytosis 
and phagocytosis) in DC and MФ is still unclear. However, our results excluded the 
possibility that FcRn is required for ICs internalization. We demonstrated that the 
internalization of ICs in MФ and DC was not affected by FcRn deficiency, this result 
is compatible with the fact that majority of  FcRn is expressed in the 
endosomes/lysosomes of  DC and MФ (183, 184), and does not bind to IgG in neutral 
pH. Hence, ICs probably access to the endosomes or phagosomes through FcγRs-
mediated endocytosis. In the endosomes, the FcγRs-ICs binding switches to FcRn-ICs 
binding. The binding of FcRn with ICs makes ICs less susceptible to protease 
digestion. This is demonstrated by the experiment that HRP alone is digested much 
easier in endosomes/lysosomes than HRP-IC (Fig. 4.6). Therefore it warrants more 
detailed studies on how the interaction of FcRn with ICs contributes to the stability of 
antigens.   
 
        In summary, the MHC class I-like molecule FcRn stabilizes the internalized ICs 
through the direct binding in acidic organelles, promotes the antigen presentation on 









       FcRn is an MHC class I-related Fc receptor for IgG. It binds IgG at acidic pH and 
releases IgG at neutral pH, which differs from other FcγRs. In addition to facilitating 
the transfer of maternal IgG to fetus or newborn, FcRn also acts as homeostatic 
receptor responsible for extending the serum half-life of IgG in adult. In IgG-related 
autoimmune diseases and infectious diseases, IgG plays a pivotal role for disease 
development and progression. As IgG level is correlated closely with the expression 
level of FcRn, understanding the function and regulation of FcRn will pave the road 
to better understand these diseases in another angle.  
 
            In this study (Chapter 2) (146), we have shown the rapid up-regulation of FcRn 
mRNA and FcRn protein in a human macrophage-like cell line, an intestinal epithelial cell 
line, and freshly isolated human monocytes after TNF-α or IL-1β treatment or in response to 
CpG or LPS. Stimulated FcRn mRNA levels were reduced in cells treated with the inhibitor 
of NF-κB p65 nuclear translocation (CAPE) or by overexpression of a dominantly negative 
IκBα. Three intronic NF-κB binding sites in human FcRn gene were identified by chromatin 
immunoprecipitation assays. A chromosome conformation capture assay demonstrated 
interactions between the NF-κB binding sequences and the FcRn promoter. Human IgG 
transcytosis on polarized human intestinal epithelial cells was also enhanced in both 
directions after exposure of the cells to TNF-α. Overall, these data indicate that FcRn 




regulated by NF-κB binding to three FcRn gene intronic regions.  
 
           However, several interesting questions still remain. First, how is FcRn regulated in 
patients with antoimmune disease or infectious disease? What is the application of FcRn 
upregulation?  Such as, autoimmune skin blistering diseases, pemphigus and pemphigo, are 
characterized by subepidermal blisters, inflammatory cell infiltration, and the linear 
deposition of IgG autoantibodies at the basement membrane zone of skin. It is very 
interesting to know whether FcRn upregulation is involved in pemphigoid initiation and 
progression. The study by Zhi Liu and Derry, C. Roopenian’s groups have shown that FcRn 
deficiency ameliorates pemphigus (200), which provides a direct link between pemphigus 
and FcRn. Second, during inflammatory cytokines or TLR ligands stimulation, what 
transcription factors are involved in the formation of loops between introns and promoter 
besides NF-κB? In our study, chromosome confirmation capture (3C) assay indicates that 
there are potential loops formed between human FcRn intronic elements and promoter region 
after TNF-α stimulation. Because of limitation of 3C assay, several issues still need to be 
clarified, where is the exact locations of loops? How many loops are formed during the 
transcription? What other factors are involved in the NF-kB mediated gene upregulation? 
What are the modifications on the epigenetic level? Third, regarding the fact that human 
FcRn gene is different from mouse FcRn gene, the transgenic mouse model containg the 
whole human FcRn locus will be very useful; it will serve as valuable tool to understand the 
FcRn regulation in the context of autoimmune diseases and infectious diseases, and to 





           Many studies have shown that IFN-γ can upregulate MHC class I genes (141). 
In the present study (Chapter 3) (194), we demonstrated that MHC class I-related 
FcRn was down-regulated by IFN-γ stimulation, and this down-regulation is 
dependent on Jak1-Stat1 signaling pathway. One Stat1 binding site was identified in 
the human FcRn promoter by ChIP assay. The mutation of Stat1 binding site blocked 
the IFN-γ-induced down-regulation of luciferase activities that were driven by FcRn 
promoter. Most frequently, dimeric Stat1 translocates into the nucleus and binds to 
the GAS sequence to activate gene expression. However, in the case of FcRn, 
activated Stat1 bound to FcRn GAS sequence and blocked FcRn transcription. 
Similarly, gene suppression by Stat1 was also observed on MMP-9 or the SR-A gene, 
even though there are no GAS elements on these genes, and Stat1 was demonstrated 
to play an indirect role through interacting with other transcription factors (156, 165). 
Thus, it is very interesting to exploit the mechanism how Stat1 switchs on and off 
genes expression. In our study, an important transcription factor, p300/CBP was 
found recruited and sequestered by Stat1, which might result in the inhibition of FcRn 
transcriptional initiation. Furthermore, this block can be rescued by the 
overexpression of p300. Exploitation of p300-Stat1 interaction merits further study 
with the goals of understanding Stat1-mediated gene regulation on epigenic level. 
More interestingly, the GAS element (TTCTTTGAA) on human FcRn has stronger 
binding affinity with Stat4 (153). Also, we found that IFN-α/β can upregulate FcRn 
expression through non-IRES element, which coincide with the demonstration that 
Stat4 can be activiated by IFN-α/β directly (201-204). So, how type I interferon-




Under normal development, the significant decrease of murine FcRn was found in the 
intestine tracts after the weaning (57). Exploitation of FcRn regulation holds promises 
for unveiling the finely tuned network of transcriptional factors and the full function 
of FcRn in the mucosal organs. 
 
The involvement of FcRn in antigen presentation was recently discovered by 
Dr.Blumberg’s group (76). In our study (Chapter 4), we described that FcRn in DC 
and MФ can stabilize the input IgG-derived immune complexes in the acidic 
condition, slow down the antigen processing, and then promote the efficient peptide 
loading onto MHC class II molecules. In DC, the nearly neutral pH in phagosome 
fails FcRn to interact with uptaken immune complexes (IC -coupled beads), which 
results in non-effect on antigen presentation. However, in MФ, the acidic pH in 
phagosomes facilitates the physical contact between FcRn and immune complexes, 
which enhances the efficient antigen processing and antigen presentation both in vitro 
and ex vivo. Therefore, the pH value in the specific organelle is the key to determine 
whether FcRn is able to involve in the antigen presentation of uptaken immune 
complexes. However, how FcRn plays its role to protect complexed-antigen from 
rapid proteolysis remains still a question. Since proteolysis is necessary for antigen 
presentation, it is interesting to determine how FcRn balances the antigen digestion 
and protection to efficiently produce antigenic epitope from an immune complex. 
These findings will provide basis and starting point for subunit vaccine engineering. 
 




How FcRn is distributed in DC and MФ remains elusive. Particularly, the expression 
of invariant chain in APC changes FcRn distribution (184). FcRn in turn is more 
prone to be delivered to the late endosome/lysosome in APC cells. In our study, we 
have also shown that FcRn traffics to the phagosome in APCs. Both late endosomes 
and phagosomes are competent organelles for antigen presentation. Therefore, 
understanding the traffic pattern of FcRn in APCs will further shed light on the 
mechanism of FcRn in antigen presentation. 
 
       It has been shown that the distribution pattern and fate of monovalent of IgG 
inside DC and MФ are different from that of multivalent antigen-antibody complexes 
(207). Monovalent IgGs are easily recycled, whereas, multivalent antigen-antibody 
complexes are destinated for the degradation (207, 208). Inconsistently, immune 
complexes can also be recycled in DC to better activate B cells (75). So, the question 
of how FcRn cooperates with other FcγRs to mediate immune complex trafficking 
will provide insightful concept to solve the discrepancy. The role of FcRn in immune 
complex trafficking could also explain FcRn-mediated antigen presentation.  
         
         FcRn, the pH-dependent Fc receptor begins to be fully recognized on its 
functional importance. In addition of its critical role of IgG transport and 
homeostasis, FcRn is involved in the antigen presentation of IgG-restricted immue 
complexes from our study. The exploitation of FcRn will be a great benefit for better 
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